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It is widely accepted that the emergence of drug-resistant pathogens is the result
of the overuse and misuse of antibiotics. Infectious Disease Society of America, Center
for Disease Control and World Health Organization continue to view, with concern, the
lack of antibiotics in development, especially those against Gram-negative bacteria.
Antimicrobial peptides (AMPs) have been proposed as an alternative to
antibiotics due to their selective activity against microbes and minor ability to induce
resistance. For example, the Food and Drug Administration approved Daptomycin (DAP)
in 2003 for treatment of severe skin infections caused by susceptible Gram-positive
organisms. Currently, there are 12 to 15 examples of modified natural and synthetic
AMPs in clinical development. But most of these agents are against Gram-positive
bacteria. Therefore, there is unmet medical need for antimicrobials used to treat
infections caused by Gram-negative bacteria.
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In this study, we show that a pro-apoptotic peptide predominantly used in cancer
therapy, (KLAKLAK)2, is an effective antimicrobial against Gram-negative laboratory
strains and clinical isolates. Despite the therapeutic promise, AMPs development is
hindered by their susceptibility to proteolysis. Here, we demonstrate that an all-D
enantiomer of (KLAKLAK)2, resistant to proteolysis, retains its activity against Gramnegative pathogens. In addition, we have elucidated the specific site and mechanism of
action of D(KLAKLAK)2 through a repertoire of whole-cell and membrane-model assays.
Although it is considered that development of resistance does not represent an
obstacle for AMPs clinical development, strains with decreased susceptibility to these
compounds have been reported. Staphylococci resistance to DAP was observed soon after
its approval for use and has been linked to alterations of the cell wall (CW) and cellular
membrane (CM) properties. Immediately following staphylococcal resistance,
Enterococci resistance to DAP was seen, yet the mechanism of resistance in enterococci
remains unknown. Our findings demonstrate that, similar to S. aureus, development of
DAP-resistance in a vancomycin-resistant E. faecalis isolate is associated with alterations
of the CW and properties of the CM. However, the genes linked to these changes in
enterococci appear to be different from those described in S. aureus.
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Chapter I
Introduction

Antimicrobial Resistance

Resistance to single antibiotics is not a new phenomenon. Although, the
first antibiotic -- penicillin-- was discovered in 1928, large-scale production did not start
until 1940. By 1944, staphylococci had become resistant to penicillin (1). Partially, this
phenotype was due to the secretion of a specific enzyme, penicillinase, able to degrade
penicillin (2, 3). Ever since, the introduction of new classes of antibiotics increased the
selective pressure on specific microbial populations resulting in the emergence of multidrug-resistant (MDR) organisms. These microbes are resistant to many classes of
antibiotics due to several different types of resistance mechanisms including: enzymatic
mechanisms of drug modification, enhanced efflux pump expression, altered membrane
permeability, and mutated drug targets.

Genetics of antibiotic resistance
Bacteria can become resistant to antibiotics through intrinsic or acquired
mechanisms. The mechanisms of acquired resistance involve chromosomal mutations,
horizontal gene transfer of resistance determinants (4) or a combination of these two
means.
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Spontaneous mutations
Spontaneous mutations occur randomly in the form of incorrect repair of DNA
damage or replication errors in actively dividing cells (5). Point mutations confer
resistance when they are able to produce a resistance phenotype, and allow growth of the
bacteria despite the presence of antibiotics (2, 6). Mutations leading to resistance usually
map to the target of antibiotics. For example, mutations in the genes encoding RpoB and
topoisomerases, which are the targets of rifampicins and fluorquinolones, confer
resistance to these molecules (7, 8). In addition, mutations in the promoter regions of
regulatory genes (9, 10) encoding for efflux or uptake systems also lead to resistance. In
the case of P. aeruginosa, reduced expression of the OprD porin leads to resistance to
carbapenems (11). Mutations that lead to the up-regulation of antibiotic-inactivatingenzymes also increase antimicrobial resistance.

Hypermutator phenotype
Normally, spontaneous mutation rates due to errors produced in the DNA
replication process in a species remain low due to the activity of molecular mechanisms
that act to repair and protect DNA. However, bacteria with high mutation rates have
been identified. The majority of the bacteria with high mutation rates (hypermutators)
have an inactive mutS or mutL gene, which leads to a defective mismatch repair (MMR)
system (12). Usually, MMR eliminates biosynthetic errors and prevents recombination
by non-identical DNA sequences (13). Hypermutable phenotypes act by accelerating the
emergence mutations responsible for antibiotic resistance (7, 14, 15).
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Adaptive mutagenesis
In addition to mutations that occur due to errors during the DNA replication
process, mutations can also occur in non- or slowly dividing cells. These mutations,
called adaptive mutations, differ from spontaneous mutations based on their occurrence
only in the presence of non-lethal selective pressure that favors them (4), such as a subinhibitory drug concentration which often arises when treatment doses of antibiotics are
not followed.

Horizontal gene transfer (HGT)
The first evidence of HGT was the recognition of the transfer of virulence
determinants between pneumococci in infected mice (16). HGT can be the result of one
of three mechanisms: (i) natural transformation (Figure 1-1) defined by stable uptake,
integration and expression of extracellular DNA; (ii) transduction mediated by
bacteriophages or (iii) conjugative transfer (Figure 1-2), where a cell-to-cell junction or
pillus mediates transfer.
Natural transformation occurs when competent bacteria uptake free extracellular
DNA molecules present in the environment. Extracellular DNA is released from
disrupted or decomposing cells, bacteriophage, or naturally excreted from living cells
(17). Competence is most often a time-limited physiological state involving up to 50
proteins (17). It is usually regulated in response to specific environmental conditions,
although some, most importantly pathogenic bacteria, are naturally competent. The
conditions that lead to bacterial cell competence are often altered growth conditions, cell
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Figure 1-1. Natural Transformation
“The steps involved in this process include the release of extracellular
DNA into the environment and the uptake of DNA into the cytoplasm of
the recipient bacterial cell that has developed a regulated physiological
state of competence. Following uptake, for the transferred DNA to persist
it must integrate into the bacterial genome through homologous
recombination or by sequence-independent, illegitimate recombination.
Plasmids that succeed in reconstituting a replication-proficient form do
not need to integrate into the host genome.”
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Microbiology (Allen et al, 2010) copyright (2010).
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Figure 1-2. Conjugative transfer.
“In the donor, the events depicted are: a, integration of the plasmid into the
chromosome by recombination between insertion sequence elements; b,
movement of a transposable element through a circular intermediate from the
chromosome to the plasmids; c, initiation of rolling-circle replication at the
mating-pair apparatus. In the recipient cell, the events depicted are: d,
recircularization; e, attack by restriction endonucleases (scissors); f,
replication; g, integration into the chromosome by an illegitimate Campbell
recombination; h, recombination between transferred chromosomal DNA and
the resident chromosome.”
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Microbiology (Allen et al, 2010) copyright (2010).
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density, starvation or nutrient access. Competence in the bacterial population can range
anywhere from 0 to 100%. Transformation begins with non-covalent binding of DNA to
the cell surface, followed by translocation across the inner membrane. With the
exception of plasmids, DNA must integrate into the bacterial genome to persist.
The transfer of DNA from donor bacteria to recipient bacteria is mediated by
infection with a bacteriophage is called transduction. There are 2 types of transduction:
generalized and specialized. Generalized transduction occurs when an individual lytic
phage carrying different sets of genes pertaining to the bacterial genome transfers the
foreign DNA to another bacterium (18). Specialized transduction occurs when individual
phage transfer the same genetic information, usually present adjacent to the insertion
site. A lysogenic phage inadvertently becomes lytic and improperly expels itself from
the genome caring the flanking host DNA sequences. Upon infection, the extraneous
DNA is transferred to another bacterium. (18).
Conjugation occurs when all or part of the donor plasmid is transferred through
direct contact between donor and recipient bacteria (Figure 1-1). The ability of the
donor bacteria to transfer its genetic material is determined by specific conjugative
plasmids; where strains of bacteria with the plasmid function as donors and those that
lack the plasmid function as recipients (18).

Modes of antibiotic resistance
Antibiotic resistance emerges by one of 4 mechanisms: (i) direct inactivation of
the antibiotic molecule (19), (ii) alteration of the target of the antibiotic (20), (iii)
reducing the concentration of the drug without modifying the drug itself, through efflux
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pumps and outer membrane permeability (21), iv) bypassing the inactivation of a given
enzyme or cellular process (22).

Antibiotic inactivation
Antibiotics can be inactivated by the production of enzymes that degrade or
modify the antibiotic molecule through hydrolysis, group transfer or redox mechanisms
(4). A classical example of inactivation by hydrolysis are the chromosomally and
plasmid-encoded β-lactamase enzymes that cleave the β-lactam ring of penicillin and
cephalosporin antibiotics. In addition to the over 200 β-lactamases identified to date (4),
over 180 extended-spectrum β-lactamases have been discovered that confer resistance to
all penicillins, third generation cephalosporins and aztreonam (4). Esterases and
epoxidases confer resistance to macrolides and fosomycin, respectively (23, 24, 25).
Transferases inactivate antibiotics by chemical substitution, leading to altered binding to
the antibiotic target. Oxidation and reduction of antibiotics has been infrequently
identified in pathogenic bacteria (26).

Target modification
Modification of the target comes in the form of peptidoglycan structure
alteration, protein synthesis interference and DNA synthesis interference, which leads to
the inability of the antibiotic to bind. Peptidoglycan is an essential component of the
bacterial cell-wall (CW), and therefore the enzymes involved in its synthesis and
assembly serve as excellent targets for antibiotics. Often, penicillin-binding proteins are
mutated; these mutations lead to decreased affinity of β-lactam antibiotics (27, 28, 29).
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In addition to penicillin binding proteins, often bacteria will acquire mutations causing
alterations of the C-terminal site of peptidoglycan pre-cursors, which are common
targets of glycopeptides.
Mutations in the bacterial 50S ribosomal subunit are a common form of
resistance to many antibiotics whose mechanism of action is interfering with protein
metabolism. For example, a post-transcriptional modification to the 23S rRNA in the
50S ribosomal subunit confers resistance to macrolides, lincosamides and streptogramin
B (30). In addition to the 23S subunit, mutations in the 16S rRNA gene are also
common and confer resistance to aminoglycosides.
Topoisomerase IV and DNA gyrase contain sites of interaction for
fluoroquinolones. This interaction causes a cessation of DNA replication and
transcription. Fluoroquinolone resistance is often the result of mutations in the structural
genes encoding for these molecules, leading to the inability of antibiotics to bind (31).

Outer membrane permeability and efflux pumps
Decreased outer membrane permeability results in reduced antibiotic uptake.
When coupled with efflux pumps increased activity, the concentration of antibiotic is
kept at very low levels inside the cell. Efflux pumps affect all classes of antibiotics and
vary widely in their specificity and mechanism (32, 33). Some pumps are very drug
specific, while others are multi-drug transporters and efflux a wide variety of unrelated
antibiotics (34).
Antibiotics must cross the outer membrane of Gram-negative bacteria to reach
their cellular target. This process is accomplished by either diffusion or self-promoted
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uptake (4). Diffusion takes place through porins or directly through the bilayer.
Mutations in porins such as number, size and selectivity will greatly alter the rate of
diffusion of antibiotics (35, 36, 37, 38, 39).

Pseudomonas aeruginosa

Microbiology
Pseudomonas aeruginosa is a non-fermentive, motile Gram-negative rod that is
ubiquitous in soil and water (40, 41). In nature, P. aeruginosa is found in many forms
such as a biofilm, attached to a surface or substrate, or in a planktonic form, as a
unicellular organism. It is tolerant to a wide variety of physical conditions, including
temperature, and is resistant to high concentrations of salts, dyes, weak antiseptics, and
many commonly used antibiotics.

Disease
P. aeruginosa is recognized as a major cause of nosocomial bacteremia and
infections associated with invasive devices, mechanical ventilation, burn wounds, or
surgeries (42). The worldwide emergence of MDR nosocomial clones has added
significantly to the ominous prognosis of P. aeruginosa infections.

Pathogenesis
P. aeruginosa has a wide host of virulence factors and produces many toxins and
surface components associated with virulence (43, 44, 45). P. aeruginosa undertake two
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main mechanisms of pathogenic behavior: i) remains confined as a chronic infection, for
example, in the lungs of cystic fibrosis (CF) patients or ii) invades tissues causing
bacteremia and pneumonia, usually resulting in septic shock and death.
In the CF chronic lung infection, P. aeruginosa usually down-regulates its toxins
(46), loses its ‘O’ side chains (47), loses its flagellum and pilli (48, 49) and expresses
alginate (mucoid coat) on the surface to protect itself from phagocytosis (50). Although
the flagellum of P. aeruginosa are down regulated in chronic infections, it plays an
important role in dispersal and adhesion to host cells (51, 52, 53, 54). These mutations
are important to the persistence of P. aeruginosa because production of these factors
would elicit an immune response, and without them the organism is able to evade the
immune mechanisms in the lungs.
P. aeruginosa employs a secretion system composed of 43 genes called the type
III secretion system (TTSS), to inject specific toxins directly into the host cell (55),
(56). Four effector proteins have been identified: ExoS, ExoT, ExoU and ExoY of
which ExoS, ExoT and ExoU have been related to virulence (57). ExoS and ExoT are
found in 70 to 100% of clinical isolates, respectively (58) and contribute to phagocytosis
inhibition. Their mechanism of action involves disruption of host cell actin cytoskeleton
resulting in cell death (59). The ExoU gene is found in only 30% of clinical isolates (59)
and encodes for phospholipase A2 (PLA2) (60, 61). The PLA2 activity of ExoU leads to
dissolution of the plasma cell membrane, followed by rapid cell death (60, 61, 62) and a
large increase in production of prostaglandins (63) leading to increased tissue damage
and excessive inflammation.
Quorum sensing (QS) is another important virulence mechanism of P.
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aeruginosa. When bacteria reach high density, they secrete a QS effector molecule
called autoinducer, which is sensed by neighboring bacteria (64). In P. aeruginosa, the
QS system regulates many processes from production of toxins to biofilm formation (65,
66, 67, 68, 69, 70, 71).

Mechanisms of Antibiotic Resistance
P. aeruginosa is one of the leading causes of nosocomial infections worldwide
(72). Besides intrinsic resistance determinants, P. aeruginosa has the ability to acquire
further resistance mechanisms making infection with this pathogen often hard to treat.
Almost all known mechanisms of antimicrobial resistance have been demonstrated in P.
aeruginosa. Often these resistance mechanisms are not present singularly but in concert
with each other, thereby conferring a multi-resistant phenotype.
The most prevalent mechanism of resistance to β-lactams is enzyme production.
In 1980, Ambler (73) described the molecular classification of β-lactamases based on the
nucleotide and amino acid sequences of the enzymes. There are 4 recognized classes
named A-D, correlating with their functional classification (74). Classes A, C and D act
through a serine based mechanism, class B are known as the metallo-β-lactamases
(MBLs) and require zinc for their action. P. aeruginosa expresses significant numbers of
enzymes pertaining to all classes (A-D).
AmpC β-lactamase is an inducible chromosomally encoded molecular class C
enzyme that is usually produced in low quantities by P. aeruginosa (75). However, in
the presence of inducing β-lactams its production increases 100-1000 times (76). Four
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carbenicillin hydrolyzing β-lactamases belong to molecular class A (77). To date, P.
aeruginosa has not been found to have plasmid mediated cephalosporinases.
PER-1 was the first fully characterized extended spectrum β-lactamase (ESBL).
It was found to be chromosomally encoded but has since been reported to be plasmid
mediated (78).
In addition to class A ESBLs, many class D β-lactamases, also known as
oxacillinases (OXA), have been identified in P. aeruginosa. The classical OXA enzyme
can confer resistance to carboxypenicillins and ureidopenicillins but not to ceftazidime
(77). However, the OXA types identified in P.aeruginosa, are able to hydrolyze
ceftaxidime, and therefore have great clinical importance. Moreover, this type of OXA
is also able to hydrolyze many other antibiotics. Their spectrum includes: cefotaxime,
cefepime, cefepime aztreonam, and moxalactam. In addition to a wide spectrum of
effectiveness, these OXA types are at most instances not suppressed by β-lactamase
inhibitors (79).
P.aeruginosa can also produce carbapenem-hydrolyzing enzymes that belong to
the molecular class B (74), known as carbapenemase or MBLs (78). Production of
carbapenemases confers resistance to all β-lactams, except the monobactam and
aztreonam.
The high molecular mass proteins OprM, OprJ, OprN present in the outer
membrane of P. aeruginosa contribute to low membrane permeability (80) and act as
components of active efflux systems with wide substrate specificity (81). Efflux also
contributes to the development of a multi-resistant phenotype and is mediated by four
genetically different three-component efflux systems: (81, 82) MexA–MexB–OprM,
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MexC–MexD–OprJ, MexE–MexF–OprN, and MexX–MexY–OprM. These three
component systems have similar structures with the first component operating as an
energy dependant pump located in the cytoplasmic membrane (MexB, MexD, MexF and
MexY). The second component functions as an outer membrane protein (OprM, OprJ,
OprN and OprM). The third protein functions as a linker between the other two proteins
and is located in the periplasmic space (MexA, MexC, MexE and MexX) (82).
OprD is a protein that forms specific channels that allow the entry of basic amino
acids and carbapenems into the cell (81). A deficiency of the OprD porins is observed in
imipenem-resistant P. aeruginosa isolates (83). Rarely, it has been observed that P.
aeruginosa can alter its penicillin binding proteins, the active site for β-lactam
antibiotics (83).
Resistance to aminoglycosides comes in the form of enzyme modification, and to
a lesser extent, decreased outer membrane permeability, target modification and active
efflux (84, 85, 86). There are 3 classes of aminoglycoside modifying enzymes (AMEs);
aminoglycoside phosphotransferase (APHs), aminoglycoside adenylyltransferases
(AADs) and aminoglycoside acetyltransferases (AACs). AMEs function by decreasing
the binding affinity of the aminoglycoside to the bacterial 30S ribosomal subunit by
attaching a phosphate, adenyl or acetyl radical to the aminoglycoside molecule (87).
Although active efflux and target modification (88) are less common, they do remain
important in conferring resistance of P. aeruginosa to aminoglycosides.
Resistance to fluoroquinolones is the result of structural changes in DNA gyrase
and active efflux (89). Mutated DNA gyrase has a low binding affinity for the quinolone
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molecules. Fluoroquinolones are also universal substrates for most all efflux systems
present in P. aeruginosa.

Acinetobacter

Microbiology
The Acinetobacter genus comprises Gram-negative, non-fermenting, non-motile,
catalase-positive, oxidase-negative, strictly aerobic bacteria. Acinetobacter species are
considered ubiquitous organisms (90, 91). A.baumannii is the most important
nosocomial Acinetobacter species. It has a low carrier rate and is found rarely (0.5%3%) on human skin (92, 93).

Disease
In a large surveillance study in the United States, it was found that between 510% of cases of ICU-acquired pneumonia were due to A. baumannii (94). In addition to
being identified as the causative agent in hospital-acquired pneumonia, A. baumannii has
also been implicated in community-acquired pneumonia, described in tropical regions of
Australia and Asia (95, 96, 97, 98, 99). Diagnosis of community acquired A. baumannii
pneumonia occurs most commonly in people with a history of alcohol abuse and some
admission to the ICU (95) and is characterized by secondary bloodstream infection and a
mortality rate of 40-60% (99). In addition to pneumonia, A. baumannii can also cause
serious bloodstream infections. In a US study of blood stream infections from 19952002, A. baumannii was the 10th most common etiologic agent (100). Sources of A.
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baumannii blood stream infections are typically line related or attributed to underlying
pneumonia, urinary tract (UTI) or wound infection (101). In patients with nosocomial
postsurgical meningitis, A. baumannii mortality is as high as 70% (102). Endocarditis
caused by Acinetobacter is not very common (103, 104, 105, 106) and usually involves
prosthetic valves. In addition, Acinetobacter-caused dophthalmitis or keratitis have
been reported in relation to contact lens usage or eye surgery (107, 108).

Pathogenesis
Although there are no known diffusible toxins or cytolysins associated with A.
baumannii, genes have been identified that are involved in pillus biogenesis, iron uptake
and metabolism, QS and the type IV secretion system (109, 110). A.baumannii is able to
form biofilms, which contributes to drug resistance and evasion of the host immune
system (111, 112). A.baumannii also often display pilli or fimbriae which are important
for adhesion leading to eukaryotic cell invasion and promotion of apoptosis of the
eukaryotic cell (113).

Mechanisms of Antibiotic Resistance
In addition to innate resistance mechanisms, A. baumannii has acquired many
foreign resistance determinants which has lead to a broad resistance profile. The most
prevalent resistance mechanism to β-lactam antibiotics is enzymatic degradation. All A.
baumannii have chromosomally encoded AmpC cephalosporinases (114, 115, 116, 117).
In many Gram-negatives this is inducible, however, in A. baumannii the over expression
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of AmpC is controlled by an upstream IS element known as ISAba1 (118, 119, 120, 121,
117).
To resist the effects of carbapenems, A. baumannii produces β-lactamases with
carbapenemase activity and serine oxacillinases known as Ambler class D OXA type.
The enzymes encoded are class D meaning that the products have a higher affinity for
imipenem than for meropenem (122, 123).
A.baumannii also expresses MBLs, an Ambler class B-type enzyme (124, 125).
MBLs are less commonly identified in A. baumannii but are 100-1000 fold more potent
then OXA (124). MBLs have hydrolytic activity toward all β-lactams except
monobactam and aztreonam. There are 5 currently described MBL groups in the
literature (126) with only 3 of these currently identified in A. baumannii.
In addition to enzymatic mechanism of resistance to β-lactams, A. baumannii can
possess many non-enzymatic resistance mechanisms including changes to the outer
membrane protein (114, 127, 128, 129), multi-drug efflux pumps (120, 130, 131) and
alteration in the affinity or expression of penicillin-binding proteins (132, 133, 134).
Genes coding for all classes (acetyltransferases, nucleotidyltransferases, and
phosphotransferases) of AMEs have been identified in A. baumannii (135, 115). In
addition, a plasmid borne gene, armA, impairs the ability of aminoglycosides to bind to
16s rRNA through methylation. Resistance to quinolones appears in the form of
described mutations in the gyrA and parC genes which lead to modifications to DNA
gyrase or topoisomerase IV and cause interference with target binding (136, 137).
Quinolones are substrates for AdeABC (130, 131) and the MATE pump, AdeM (138).
Resistance to tetracyclines and glycylcyclines in A. baumannii is the result of efflux
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through tet-a and tet-b (139, 140, 141) and the AdeABC pump (131). In addition, A.
baumannii can employ ribosomal protection to resist the effects of tetracyclines
mediated by tet(M) and tet(O) determinants. Recent reports have demonstrated in vitro
resistance of A. baumannii to polymyxins, but the mechanism remains unknown (141,
142). Trimethoprim and sulfamethoxazole resistance in A. baumannii is becoming
prevalent in many areas (143). Recently, genes encoding for resistance to trimethoprim
(dhfr) and resistance to chloramphenicol (cat) have been reported (144).

Escherichia coli

Microbiology
E. coli is a rod-shaped, Gram-negative, non-sporulating facultative anaerobe that
grows on a variety of substrates, and is a member of the normal flora in mammals (145).
Its optimal growth occurs at 37°C, but some laboratory strains can grow in temperatures
up to 49°C (146).

Disease
Normally, E. coli doesn’t cause disease and co-exists with its host for a lifetime,
however, there are 3 general clinical syndromes that can result from infection with a
virulent E. coli: sepsis/meningitis, enteric/diarrheal disease, and urinary tract infections
(UTIs) (145).
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Pathotypes and pathogenesis

Enteropathogenic E. coli (EPEC)
EPEC was the first pathotype of E. coli to be described. Currently, EPEC is an
important cause of fatal infant diarrhea in developing countries (147). The TTSS is
activated in EPEC following binding to epithelial cells. Following activation, effector
proteins including Tir, and numerous other molecules are translocated into the host cell.
EPEC will then bind to the host cell through an interaction of intimin with Tir.
Following this interaction there is activation of protein kinase C (PKC), myosin lightchain kinase, phospholipase Cγ and mitogen-activated protein (MAP) kinases which lead
to nuclear factor kappa B (NF-kB) activation and IL-8 production (147, 148, 149).
Diarrhea due to EPEC results from multiple mechanisms including inflammation, ion
secretion and increased intestinal permeability (145).

Enterohaemorrhagic E. coli (EHEC)
EHEC is infective at a very low dose (<100 cells) and causes bloody and nonbloody diarrhea and hemolytic uremic syndrome (HUS) (145). The main virulence
factor of EHEC is Stx or verocytotoxin (VT), which in addition to local damage to the
colon, damages the renal endothelial cells of the kidneys. Stx is produced in the colon
and travels in the bloodstream to the kidneys where it binds to the target cell surface and
cleaves ribosomal RNA leading to loss in protein synthesis (150). This leads to renal
inflammation (151) through cytokine and chemokine production and this damage leads
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to HUS. Besides Stx, most EHEC strains have a type III secretion system and other
effector proteins present in EPEC.

Enterotoxigenic E. coli (ETEC)
ETEC is the main cause of diarrhea in travelers in developing countries and is an
important cause of childhood diarrhea in the developing world (147). ETEC attaches to
and colonizes the surface of the mucosa of the small bowel and secretes heat-labile (LT)
and heat-stable (STs) enterotoxin. LT causes a permanent activation of adenylate cyclase
through its ADP-ribosyl transferase activity leading to increased levels of intracellular
cAMP. The increased levels of cAMP induce activation of cAMP-dependant kinases
and eventual activation of the CF trans-membrane conductance regulator (CTFR).
CTFR is the main chloride (Cl-) channel in epithelial cells and the result of its
phosphorlyation is increased Cl- secretion and diarrhea (152). LT also causes an
increase in secretion of water and mucous as well as an inhibition of absorption through
stimulation of prostaglandin synthesis and the enteric nervous system (152).
STs have two sub-classes: STa and STb, of which only the STa class has been
associated with disease in humans (147). When STa binds to its guanylate cyclase
receptor it stimulates its activity leading to increased intracellular cGMP. The increased
intracellular cGMP activates kinases, which increase secretion of water and mucous.

Enteroaggregative E. coli (EAEC)
EAEC is the cause of persistent diarrhea in both children and adults and is
characterized by its autoaggregative adherence pattern in which bacteria adhere to each
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other in a ‘stacked brick’ pattern (147). EAEC colonizes the intestinal mucosa of the
colon causing secretion of enterotoxins and cytotoxins (153) and induces significant
mucosal damage (154). There are several toxins and virulence factors attributed to
EAEC. Although no single factor has been directly proven, epidemiological studies have
implicated similar virulence factors of other enteric pathogens (155, 156).

Enteroinvasive E. coli (EIEC)
EIEC pathogenesis is characterized by dissemination into epithelial cells by cell
penetration, lysis of the endocytic vacuole and intracellular multiplication followed by
movement through the cytoplasm and extension into adjacent epithelial cells (145). It
has been shown that EIEC can induce apoptosis in infected macrophages (157). In
addition to the type III secretion system that is essential for the invasiveness of EIEC
(158), additional virulence factors such as the serine protease Sep A and the aerobactin
iron-acquisition system have been described.

Diffusely adherent E. coli (DAEC)
DAEC are the cause of diarrhea in children older than 12 months of age (147).
The cytopathic effect induced by DAEC strains is distinguished by long cellular
extensions that wrap around the adherent bacteria (159).

Uropathogenic E. coli (UPEC)
There is a small number of O serogroups of E. coli that cause uncomplicated
cystitis and acute pyelonephritis and this subset of E. coli is distinct from the commensal
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E. coli strains found in the lower colon. There is no single phenotypic profile that causes
UTIs but specific adhesins and fimbriae aid in colonization (160, 161). In addition,
several toxins attributed to UPEC have been described, including cytotoxic necrotizing
factor, haemolysin and the auto transported protease Sat (161).

Meningitis/sepsis-associated E. coli (MNEC)
MNEC is the most common cause of Gram-negative neonatal meningitis (162,
163). Strains that cause meningitis are usually of the K1 capsule type and comprise only
a small number of O serogroups.

Mechanisms of antibiotic resistance
E. coli is often resistant to β-lactam antibiotics, this resistance is usually
mediated by one or more β-lactamases enzymes (74, 164). Ampicillin resistance is
usually mediated by the OXA type of β-lactamases (79, 164). Quinolone resistance is
most often present in the form of alteration of the target of the quinolone molecule, DNA
gyrase. Aminoglycoside resistance is most often in the form of aminoglycoside
modifying enzymes (165, 166).

Klebsiella pneumoniae

Microbiology
K. pneumoniae is a Gram-negative, non-motile, facultative anaerobic,
encapsulated lactose fermenting bacteria. The primary reservoir for K. pneumoniae is
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humans, although it can be found in soil and water (167, 168, 169). Carrier rates in
humans ranges from 1 to 6 percent in the nasopharynx (although, higher rates have been
seen in alcoholic patients), 5-38 percent in stools, and is rarely carried on skin (170).
These carrier rates, however, are dramatically increased in hospitalized patients with 77,
19 and 42 percent carrier rates in the stool, pharynx and hands, respectively (170).
These higher rates of carriage are related to the use of antibiotics (170, 171).

Disease
K. pneumoniae is most often described in patients with occupational exposure
(often in the paper industry) (172) or as a nosocomial pathogen in patients with impaired
host defenses such as alcoholism, malignancy, chronic obstructive pulmonary disease,
glucocorticoid therapy, renal failure, diabetes mellitus, and hepatobillary disease (173,
174, 175, 176, 177, 178). In the nosocomial setting it has been associated with urinary
and pulmonary tract infection, and bacteremia. K. pneumoniae causes, although less
commonly, community-acquired infection pneumonia, UTI, and a liver abscess
syndrome (primarily in east Asia) that has been associated with metastatic infections.

Pathogenesis
The pathogenesis of infection with K. pneumoniae is mediated by 5 major
virulence factors: i) capsular serotype, ii) hypermucoviscosity, iii) lipopolysaccharide,
iv) siderophores and v) pili (170). There are 77 different serotypes of capsular
polysaccharide antigens of K. pneumoniae, varying worldwide by region (179, 180, 181,
182, 183, 184). In human urine and sputum clinical isolates the most common serotype
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for capsular antigen is the K2 serotype (179). It has been demonstrated that the most
common serotypes in Europe and North America are 2, 21 and 55 (179). In contrast, the
most common serotype in liver abscess, bacteremia and septic endophalmitis in Taiwan
is K1 (178, 180-182, 183) and the most common serotype in Australia from urinary,
sputum and blood isolates is K54 (183). The K1 and K2 capsular polysaccharide antigen
expressing isolates have been shown to have a higher lethality when administered to
mice than the non-K1/K2 isolates (185). The 2 major reasons for increased virulence of
the K1/K2 serotype isolates are: i) these serotypes are more often hypermucoviscous
then non K1/K2 strains and ii) the lack of mannose or rh-mannose sequences that protect
the isolates from lectin mediated phagocytosis (186).
Isolates that have the hypermucoviscosity phenotype in K. pneomuniae are more
resistant to complement-mediated serum killing than those lacking this phenotype (187,
188). Hypermucoviscosity has been shown to correlate to a higher rate of invasive
infection when compared to non-invasive strains (187). In addition, many clinical
studies have shown a direct association between destructive tissue abscess syndrome and
the hypermucoviscosity phenotype (181, 189, 190, 191).
The lipopolysaccharide O side chain can inhibit C1q and C3b in serum from
binding to the K. pneumoniae cell membrane rendering it immune to complementmediated membrane damage (192, 193). K. pneumoniae isolates that lack the
lipopolysaccharide O side chain have been shown to have increased sensitivity to
complement-mediated killing (192, 188, 193). In addition to inhibiting complementmediated killing, K. pneumoniae lipopolysaccharide can trigger cytokine pathways by
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acting as an endotoxin leading to septic shock and an increase in the propensity for
bacteremia (194).
Synthesis of siderophores is important to many bacteria, including K.
pneumoniae, due to the low levels of iron present in the microenvironment of an
infection (195). The two main siderophores produced in K. pneumoniae are
enterobactin, which is synthesized by most all strains, and aerobactin, which is found in
less then 10 percent of strains (196, 197, 198). K. pneumoniae strains that produce
aerobactin are more virulent than those that do not, and it has been shown that the
transfer of the aerobactin gene into a non-virulent K. pneumoniae strain can enhance
virulence by 100-fold (199).
K. pneumoniae expresses 2 different types of pili, named type 1 and type 3 (200).
Type-1 pili are found in all members of the Enterbacteriaceae and mediate adherence to
epithelial cells (201). The gene encoding these pili (fimH) is present in more than 98%
of K. pneumoniae (189, 202). The type 3 pili contribute to virulence in K. pneumoniae
by attaching to epithelial cells (203) leading to colonization and proliferation followed
by infection. In addition, type 3 pili are a requirement for K. pneumoniae to form
biofilms (204).

Mechanisms of antibiotic resistance
Drug resistance in K. pneumoniae is due to expression of chromosomal AmpC βlactamases that are constitutive and inducible, as well as plasmid-encoded ESBLs and
carbapenemases.
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Enterococci

Microbiology
Enterococci are a Gram-positive facultative anaerobic organism that grows in
chains and are distinguished by 4 criteria: i) react with group D antiserum, ii)
demonstrate pyrrolidonyl arylamidase and leucine aminopeptidase, iii) grow in 6.5%
sodium chloride and iv) hydrolyze esculin in the presence of bile. Enterococci are a part
of the normal intestinal flora and have recently become an issue as a multi resistant
pathogen in the hospital setting (205, 206).

Disease
Nosocomially, the most common infections due to enterococci are UTIs followed
by intra-abdominal and pelvic infections (207). Enterococci are also the causative agent
in surgical wound infections, neonatal sepsis, meningitis, bacteremia, and endocarditis
(208).

Pathogenesis
Several studies have identified virulence factors in enterococci, the most
important and prevalent being aggregation substance (AS), surface protein, gelatinase
and fsr two-component system, pilli, MSCRAMMs (microbial surface components
recognizing adhesive matrix molecules), CW and capsular polysaccharides, and
glycolipids. AS are a group of surface proteins that direct bacterial aggregation and
whose expression is induced by a peptide pheromone (209, 210, 211). In addition to
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bacterial aggregation, AS have been reported to facilitate bacterial internalization (212,
213, 214). An enterococcal surface protein of great interest is the product of the gene
esp (215, 216). Proteins encoded by the esp gene have been identified as factors
involved in colonization of the urinary tract (217). Gelatinase is a secreted bacterial
protease controlled by the fsr two-component system and has been shown to have an
important role in biofilm formation (218). The pilli of enterococci facilitate biofilm
formation and adhesion, contributing to the pathogenesis of biofilm-associated diseases
such as endocarditis (219) and UTIs (220, 221). MSCRAMMs contribute to
pathogenesis of enterococci by interacting with the extracellular matrix leading to
colonization of human tissues. The CW of enterococci is important for virulence
because it prevents complement activation and killing by phagocytes through evasion of
the host’s immune system (222). Glycolipids play an important role in virulence and are
involved in forming a permeable layer between the cytoplasm of the host cell and the
environment (223, 224).

Mechanisms of antibiotic resistance
Enterococci have an intrinsic resistance to low levels of aminoglycosides and
clindamycin, nalidixic acid, lincosamides, low levels of penicillinase susceptible
penicillin, penicillinase resistant penicillins and cephalosporins (225). Because their
penicillin binding proteins (PBP’s) are low affinity, the enterococci retain their ability to
synthesize the CW in the presence of these antibiotics (225). In addition to intrinsic
resistance to β-lactams, enterococci can become tolerant to penicillin in as few as 5
doses (207) and can produce β-lactamase enzymes (225-227, 228). Low-level resistance
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to aminoglycosides is a trait shared by all enterococci and is attributed to low uptake of
these molecules (225). Enterococci can acquire high level aminoglycoside resistance
through the expression of AMEs that are transferable from one organism to another the
most common of which are (i) dual function 2’phosphotransferase and 6’acetyl
transferase that confer resistance to all aminoglycosides except streptomycin, (ii)
3’phoshotransferase which confers resistance to kanamycin and penicillin-amikacin, (iii)
6’adenyl transferase which inactivates streptomycin (225). An important clinical
problem is the rapid spread of enterococci that have also become resistance to
glycopeptides (229, 230-232) following the first report of vancomycin-resistant
enterococci (VRE) in the 1980s (233). Most commonly resistance to glycopeptides in
enterococci has been reported in 3 phenotypes i) Van A which is inducible and confers
high level resistance to vancomycin and teicoplanin, ii) Van B which confers varied
levels of resistance to vancomycin and is sensitive to teicoplanin and iii) Van C which
confers constitutive low level resistance to vancomycin and sensitivity to teicoplanin
(234, 235).

Staphylococcus aureus

Microbiology
S. aureus is Gram-positive, catalase and coagulase positive, mannitol
fermenting, non-motile common commensal organism found in 30-50% of healthy
humans. S. aureus is an aerobic organism but can tolerate growth at low oxygen, under
high osmotic pressure and at a wide temperature range (236).
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Disease
Although S. aureus is a common commensal, it is also an opportunistic pathogen
that can cause many diseases in humans and other species. Infections caused by S.
aureus range from mild skin diseases to invasive illness (236). Prolonged infections
lead to development of osteomyelitis or necrotizing fasciitis (237, 238). S. aureus sepsis
is usually associated with bacteremia, and can be secondary to bacterial infection of the
urinary tract, bone, kidney, or lungs (239, 240). S. aureus is a causative agent of toxic
shock syndrome (TSS) and gastroenteritis (241). In addition, S. aureus is the most
frequently isolated pathogen from patients suffering from ventilator-associated
pneumonia (242).

Pathogenesis
S. aureus possesses both secreted and structural products that contribute to its
virulence and pathogenesis. It has a variety of surface attachment-improving agents
known as MSCRAMMs that mediate attachment to host cells and therefore initiate
colonization. S. aureus exotoxins and super antigen toxins have been implicated in
gastroenteritis and TSS (243).

Mechanisms of antibiotic resistance
Methicillin resistant S. aureus (MRSA) accounts for the majority of nosocomial
infections (244). Nosocomial strains of methicillin resistant S. aureus known as
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hospital-associated S. aureus (HA-MRSA) infects those that have established risk factors
such as prolonged hospitalization or antimicrobial therapy, surgical procedures, dialysis,
indwelling vascular devices, and proximity to patients in the hospital who are infected or
colonized with MRSA (236). HA-MRSA strains are usually resistant not only to
methicillin but also to many classes of antibiotics (245). MRSA infecting individuals
outside of the healthcare facilities is referred to as community-associated MRSA (CAMRSA) (246, 247). Contrary to HA-MRSA, CA-MRSA strains are mostly resistant to βlactams (248). Although CA-MRSA is traditionally less drug resistant, clusters of
disease of a multidrug-resistant USA300 isolates that contain multiple resistance genes,
rendering it resistant to β-lactams, fluoroquinolones, tetracycline, macrolide,
clindamycin, and mupirocin, surfaced in the community (249, 250).
Daptomycin is a lipopeptide antibiotic that was approved by the United States
Food and Drug Administration (FDA) in 2003 for treatment of complicated skin and soft
tissue infections caused by bacteria, including methicillin-resistant Staphylococcus
aureus (Cubist Pharmaceuticals, Inc. 2003. (Daptomycin (Cubicin) package literature,
Cubist Pharmaceuticals, Inc., Lexington, Mass.). However, treatment failure due to
daptomycin resistance has been recently reported (251).

Antimicrobial peptides (AMPs)

AMPs are short amino acid sequences derived from larger precursors. They are
present in many organisms ranging from prokaryotes to humans. These peptides have an
ancient lineage and are widespread throughout the plant and animal kingdoms, which
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suggests that they have played an integral part in the evolution of multicellular
organisms. These peptides are used as potent broad-spectrum antimicrobial agents with a
diverse range of targets; the presence of a lipid membrane being the only common
characteristic among their targets (252, 253, 254). AMPs are one of the earliest
developed molecular effectors of innate immunity, and beyond antimicrobial effects,
these peptides have been shown to confer many functions in wound healing (255),
chemotaxis (256), and the induction of adaptive immune responses to foreign antigens
(257). Almost all antimicrobial peptides share a common composition consisting of
hydrophobic and hydrophilic cationic amino acids that confer an amphipathic structure
(258).
Amphipathic alpha helices have been reported in a variety of proteins (259) and
are defined by their opposing polar and non-polar faces oriented along a helical axis.
These helices make up 50% of the alpha helices found in soluble globular proteins (260,
261). There are a variety of purposeful characteristics attributed to this class of helices,
such as lipid association, membrane perturbation, hormone-receptor catalysis,
transmembrane signal transduction, regulation of kinase-calmodulin signal transduction
and transmembrane helical bundle formation (259).
AMPs are divided into 5 major groups according to their amino acid composition
and structure (262, 263, 261). The first class of AMPs known as the anionic peptides are
small peptides present in surfactant extracts, airway epithelial cells and bronchoalveolar
lavage fluid (261, 264, 265). These anionic peptides require zinc as a cofactor and are
active against both Gram-negative and Gram-positive bacteria. Cationic peptides are
enriched for a specific amino acid. These peptides lack cysteines and are mostly linear
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although some form extended coils. There is also a subgroup of anionic and cationic
peptides that contain cysteines and form disulphide bonds and stable β-sheets. This
group of AMPs covers human and insect defensins. An additional subgroup includes
anionic and cationic peptides that are fragments of larger proteins. These are similar in
structure and composition to the other classes of antimicrobial peptides but their role in
innate immunity is not clear. The final class of antimicrobial peptides are the linear
cationic α-helical peptides, which usually contains less then 40 amino acids and can have
a hinge or ‘kink’ in the middle (266, 267). When in an aqueous environment, these
peptides are highly disordered; however, when in the presence of SDS micelles, lipid A,
phospholipid vesicles and liposomes, these peptides will convert into an alpha helix
(262).
The mechanism of action of amphipathic AMPs has been fairly well defined
(268). Three main steps must take place for AMP-mediated cell killing to occur: (i)
attraction of the peptide to the cell surface, (ii) attachment of the peptide to the
cytoplasmic membrane and (iii) peptide insertion followed by membrane
permeabilization. There are 6 main characteristics that affect antimicrobial activity and
specificity: size, sequence, charge, conformation and structure, hydrophobicity and
amphipathicity. Currently, there are three widely accepted models of peptide insertion
and permeabilization of the membrane (Fig. 1-3, (268)). The carpet model describes the
parallel attachment of the peptides to the surface of the lipid bilayer where the anionic
phospholipid head groups on the outer surface of the membrane form a thick layer or
‘carpet’ (269). At high concentrations these peptides are proposed to disrupt the
membrane, similar to detergent forming micelles (270, 271), leading to the loss of
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Figure 1-3. Modes of action of
antimicrobial peptides.
(A) Carpet model.
“In this model, the peptides disrupt the
membrane by orienting parallel to the
surface of the lipid bilayer and forming an
extensive layer or carpet. Hydrophilic
regions of the peptide are shown coloured
red, hydrophobic regions of the peptide are
shown coloured blue”
(B) Barrel stave model.
“In this model, the attached peptides
aggregate and insert into the membrane
bilayer so that the hydrophobic peptide
regions align with the lipid core region and
the hydrophilic peptide regions form the
interior region of the pore. Hydrophilic
regions of the peptide are shown coloured
red, hydrophobic regions of the peptide are
shown coloured blue.”
(C) Torodial pore model.
“In this model the attached peptides
aggregate and induce the lipid monolayers
to bend continuously through the pore so
that the water core is lined by both the
inserted peptides and the lipid head groups.
Hydrophilic regions of the peptide are
shown coloured red, hydrophobic regions of
the peptide are shown coloured blue.”

Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Microbiology (Brogden, 2005) copyright (2005).

33

membrane integrity (Figure 1-3A; (268)). The barrel stave model (Figure 1-3 B, (268))
consists of the insertion and aggregation of the peptides in the lipid bilayer. The
aggregation results in the formation of a pore where the hydrophilic regions of the
peptide lies in the inner core of the aperture (268). The third proposed mechanism of
action is the toroidal pore model (Figure 1-3C, (268)). In this model, the peptide attaches
to the surface of the membrane, aggregates and induces bending in the lipids so that the
interior of the pore is lined with the lipid head groups and the inserted peptide (272).
Although these three theoretical models seem distinct, it has been proposed that they are
likely related and peptide concentration (273).

Modified peptides in current use and testing
There are many examples of modified host defense peptides and synthetic AMPs
that have entered into human testing (274, 275). Currently, there are 12-15 in different
stages of clinical development (275) however, the only peptide antibiotics currently used
are Polymyxin B/E, Gramicidin S and daptomycin. Unfortunately, both the polymyxins
and Gramicidin S are only used topically and not used systemically because they have
been shown to be extremely toxic (275). There has been an effort to modify both
peptides to make them less toxic and although it has not been successful for Gramicidin
S there is a modified form of Polymyxin that is currently used systemically for lung
infections of CF patients (275). The FDA, however, approved Daptomycin, in 2003 for
the treatment of skin and skin-suture infections caused by susceptible Gram-positive
organisms.
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Daptomycin
Daptomycin is a 13-member amino acid cyclic lipopeptide with a decanoyl sidechain (276) that has bactericidal activity against Gram-positive organisms. Daptomycin
is produced by Streptomyces roseosporus as a fermentation product (277-280, 281). The
proposed mechanism of action of Daptomycin is identical to that of antimicrobial
peptides described previously, insertion into the bacterial cell membrane causing
depolarization, although the proposed method of cellular death is arrest of DNA, RNA
and protein synthesis (276, 282), not cell lysis.

KLA peptides
One type of peptide that has been thoroughly studied is a group of α-helical
amphipathic peptides derived from the model peptide KLALKLALKALKAALKLANH2 originally used for studying the interactions between peptides and lipid interfaces
(283, 273, 284, 285, 286, 287, 288). These derivatives are collectively called the KLAderived peptides.
(KLAKLAK)1-3 is a KLA-peptide that was originally tested for its ability to kill
both eukaryotic and prokaryotic cells by the McLaughlin group in 1996 (289).
Jadvapoor et al. designed several different KLA-peptides to determine the effect of
length, sequence, and structure on biological activity. It was found that all of the leucineand alanine-containing peptides of the same length had similar MIC values. In addition,
it was shown that the 7-mers were inactive and the leucine-containing 21-mers were 2
times as potent at killing bacteria as the 14-mers, while maintaining low mammalian-cell
toxicity (289).
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Obstacles for clinical use of antimicrobial peptides
The major issues for clinical use of AMPs as antibiotics are the same issues faced
with development of most forms of antibiotics: (i) high cost of commercial scale
synthesis, (ii) toxicity, (iii) proteolytic degradation/inactivation, (iv) resistance and (v)
poor distribution in the body. The first issue, cost of synthesis, is important to consider
because production costs for peptides is generally higher than the cost to produce
‘conventional’ antibiotics. Toxicity is important to consider because for an antibiotic to
be effective it must be highly selective towards bacterial cells while having minimal
toxicity against eukaryotic cells. Often AMPs have considerable hemolytic activity
(290) which hinders their use as systemic antimicrobials, and restricts their use to topical
applications. Development of peptides that have a reduced toxicity and enhanced
antimicrobial activity is possible with the understanding of features that lead to
selectivity of the peptide. Proteolytic degradation of AMPs is a common problem, with
most peptides being degraded, or bound by proteins in the blood stream and therefore
rendered inactive. Commonly, peptide structures are modified so that they are no longer
recognized or degraded by proteolytic enzymes (291). This approach has been
successful with a number of peptides including magainin analogues (292) where
tyrosines are substituted with β-tyrosines that are shortened by one carbon unit in the
side chain. The substitution allows the peptide to have the same structure as the
naturally occurring peptide as well as have a greater stability. It can be assumed that if
peptide interaction with bacterial membranes leading to lysis of bacterial cells is
membrane receptor dependant, then that receptor would require a specific chirality of the
peptide to be functional. However, it has been shown that the enatiomeric forms of
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AMPs with all D-amino acids have equal activities when compared to their L
counterparts (293, 294, 295). Additionally, D-form AMPs have a higher stability against
proteolytic degradation (296, 297).
The issue of resistance is not as serious of a concern with AMPs because it is
assumed that resistant strains will not easily arise because the target of most AMPs is the
bacterial membrane, a structure that it is essential for the bacterium’s survival. This
assumption is strengthened by the observation that AMPs have been found in organisms
for millions of years with only a few incidences of resistance ever demonstrated.
Poor distribution of AMPs this can be overcome with site-specific administration
and targeting of the peptides.

Significance of this research

Currently, it is estimated by the National Institute of Allergy and Infectious
Disease that over 70% of hospital-acquired infections are resistant to at least one of the
antibiotics used to treat them. Routine use of antimicrobial agents has reduced the threat
posed by infectious diseases and--along with improvements in sanitation, housing,
nutrition, and wide-spread immunization programs--has led to a marked reduction in
deaths from diseases that were previously widespread, untreatable, and frequently fatal.
However, the overuse and misuse of these antimicrobial agents has lead to an increase in
resistant organisms, which have spread through many hospitals and communities.
According to NIH estimates, between 5-10% of all hospital patients develop an
infection, leading to an increase of about $5 billion in annual U.S. healthcare costs.
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The rise of multi-drug resistance represents a clear need for new, novel
antibiotics to combat these resistant infections; however, antimicrobial research and
development of new antibiotics is lagging far behind the ability of organisms’ ability to
acquire resistance. In the 1930s and 1940s there were 4 new classes of antibiotics
introduced: sulphonamides, β-lactams, aminoglycosides and chloramphenicol.
Following these developments in the 1950s and 1960s there were 6 more classes of
antibiotics that were developed and approved: tetracycline, macrolides, glycopeptides,
rifamycins, quinolones and Trimethoprim. Following 4 decades of initial discovery,
from the 1970s to the 1990s there were no new antimicrobial classes approved, and since
2000 there has only been approval for a few new classes of antimicrobials:
oxazolidinones, cyclic lipopeptides and glycylcyclines, all of which are approved for the
treatment of Gram-positive pathogens.

The time required to take an antibiotic from its

discovery to market is around 8-12 years (298). Although there is a limited number of
antimicrobial agents recently approved or in the late stages of development, these are
directed solely toward Gram-positive pathogens leaving a lack of antibiotics in the
development stages to take on the present problem of multi-resistant Gram-negative
pathogens (299, 300). The current options to treat MDR infections are becoming limited
as these bacteria expand their ability to evade existing antibiotics by developing of
various resistance mechanisms. Organisms of great concern due to the ability to become
multi-resistant are P. aeruginosa, K. pneumoniae, E. coli, E. faecalis, A. baumannii and
S. aureus.
In this study we have shown that a synthetic AMP able to disrupt bacterial
membrane non-specifically is active against Gram-negative organisms such as P.
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aeruginosa, K. pneumoniae, E. coli and A. baumannii, regardless of their antibiotic
resistance profiles. Although the scientific community does not see development of
resistance to AMPs as a concern, reduced sensitivity of S. aureus and E. faecalis to denovo AMP, DAP, emerged as a result of treatment. Resistance associated with DAP
include, most importantly, modifications to the thick peptidoglycan layer surrounding
the CM of Gram-positive organisms. Since this is a Gram-positive specific cell feature,
the mechanism of resistance related to changes in the peptidoglycan layer is also specific
to Gram-positive cells.

39

Chapter II
Materials and Methods

40

Chapter II
Materials and Methods

Media and growth conditions:
Gram-negative bacterial isolates. P. aeruginosa 10145, A. baumannii 19606 and E.
coli strain 25922 were obtained from ATCC. Pseudomonas aeruginosa PAO1 and PA14
were provided by Dr. Frederick M. Ausubel, Harvard University. Gram-negative clinical
isolates were provided by the Clinical Microbiology Laboratory at St. Lukes Episcopal
Hospital. All strains were grown at 37°C in cation-adjusted Mueller Hinton broth (CAMHB) unless otherwise stated. The biofilm inhibition assays were performed in CAMHB and 10% FBS-RPMI.

E. faecalis bacterial isolates. The two vancomycin-resistant E. faecalis isolates used
were recovered from the bloodstream of a 64-year-old woman (301). The first isolate
(daptomycin-susceptible) was recovered after the administration of linezolid and
ciprofloxacin (daptomycin MIC, 1 µg/ml). The second isolate (daptomycin MIC 16
µg/ml) was obtained from the blood of the same patient two weeks after the start of
daptomycin and amikacin therapy. The daptomycin resistant isolate exhibited the same
pulsed field gel electrophoresis pattern and had identical susceptibilities to antibiotics as
the parental susceptible isolate, except for daptomycin (301). Both isolates were grown
in brain heart infusion broth.

D(KLAKLAK)2

was obtained from Poly-Peptide-Labs.
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Stability assays. The stability of D(KLAKLAK)2 compared to L(KLAKLAK)2 in the
presence of human liver microsomes was determined by mass spectrometry . Briefly, 5
µl of human liver microsomes (pooled from multiple donors; BD Biosciences) were
diluted in 75 µl of 50 mM potassium phosphate buffer pH 7.4. D(KLAKLAK)2 and
L(KLAKLAK)2

were added to the mixture (10 µl of a 10 mg/ml solution in water) and

warmed for 5 minutes at 37°C. The reaction was started with the addition of 10 µl of 20
mM NADPH in phosphate buffer. Aliquots (10 µl) were removed pre- and post-addition
of NADPH at 1, 10, 30 and 60 minutes and 24 hours. The reactions were stopped with 5
µl of 100% trifluroacetic acid. All samples were frozen at -80°C until processed by
matrix assisted laser desorption/ionization time-of-flight (MALDI) with double time-offlight (TOF2) detection.

MALDI-TOF2 mass spectroscopy. The samples were centrifuged at 13,200 rpm for 30
minutes at 4oC to remove liver microsomal debris and then 2 µl of each sample was
added to 198 µl of 0.1% TFA solution. Samples were then further diluted 1:10 in αcyano-4-hydroxyl cinnamic acid (αCHCA; 10 mg/ml in 50% acetonitrile 0.5% TFA).
Each sample was loaded to 3 spots on a MALDI-TOF plate and MS data acquired on
each spot in duplicate. 13C-D(KLAKLAK)2 was used as the internal standard for
quantification. Quantification was performed by integrating the peak area of individual
spectra and was graphically displayed relative to the internal control.

Susceptibility assays (MIC). Antimicrobial susceptibility testing was performed as
recommended by the NCCLS (CLSI document M100-S16 CLSI). All bacterial isolates

42

were tested by broth micro dilution in CA-MHB. After incubation for 18h at 37°C, the
MIC is defined as the lowest concentration of the antimicrobial agent that inhibits visible
growth of the tested isolate as observed with the unaided eye. All experiments were
performed in triplicate.

Time-kill curves. Overnight bacterial cultures were diluted in fresh medium, and
allowed to reach exponential phase of growth. Increasing concentrations of peptide
and/or antibiotic were added and the cultures were incubated at 37°C with shaking for up
to 24 hours. To determine viable bacteria, aliquots were taken at 4, 10 and 24 h after
treatment and dilutions were plated onto LB agar. The plates were incubated at 37°C and
the colony forming units (CFU) were counted after 24 h. All assays were performed a
minimum of 3 times with representative data shown.

Synergistic assays. The synergistic activity between D(KLAKLAK)2 and piperacillin
was assayed by time kill curves in CA-MHB as described earlier (302). Briefly, the
samples were set up using concentrations of D(KLAKLAK)2 and piperacillin at ½ the
MIC, as determined by broth dilution. One sample of each D(KLAKLAK)2 alone,
piperacillin alone, D(KLAKLAK)2 and piperacillin together and a control with no
antibiotics were assayed.

Biofilm assays. P. aeruginosa PAO1 biofilm was grown as described previously (303).
Briefly, PAO1 overnight culture was diluted 1:100 in LB or 10% FBS RPMI into 96well plates and incubated for 24 hrs at 37°C without agitation. To assess the effect of
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D(KLAKLAK)2

treatment on the biofilm, increasing concentrations of peptide diluted in

LB or 10% FBS RPMI were added to the 24hr-old biofim. The next day, P. aeruginosa
biofilm was fixed with 4% paraformaldehyde and stained with 0.1% crystal violet (CV)
for 10 min at room temperature. Excess stain was removed with water and the plates
were dried overnight at room temperature. CV stain was dissolved in 95% ethanol and
the absorbance of a 1:5 a dilution in 95% ethanol was measured at 540 nm. All assays
were performed a minimum of 3 times with mead of the 3 experiments shown.

Growth phase-dependent activity. The ability of D(KLAKLAK)2 to induce membrane
permeability was investigated using the highly sensitive Baclight kit (Invitrogen).
Overnight cultures of P. aeruginosa PAO1 and PA14 were diluted 1:100 in media. Six
milliliter aliquots were removed before resuspension (stationary phase), 30 minutes after
resuspension (lag phase), 1h after resuspension (early exponential phase) and 2 hours
after resuspension (late exponential phase). Bacteria were washed in PBS and treated
with increasing concentration D(KLAKLAK)2 or 70% isopropanol. After 1 hour, bacteria
were collected, washed and resuspended to OD600 of 0.03. An equal mixture of SYTO9
and propidium iodide (3ul) was added to each 1 ml of sample. The samples were
incubated 15 minutes at room temperature in the dark. Images were acquired on an
Olympus IX71inverted microscope attached to a Lumen 200 Fluorescene Illumination
system with fluorescein and Texas Red bandpass filter sets made by Prior Scientific.
Images were collected on the Slidebook 5.0 software.
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P. aeruginosa electron microscopy. P. aeruginosa was grown to McFarland’s standard
0.5 as described above. Bacterial cells were recovered by centrifugation, resuspended in
saline and treated with freshly prepared D(KLAKLAK)2 at varying concentrations. The
organisms were exposed to D(KLAKLAK)2 for 25 minutes. Bacteria were collected,
washed and fixed with a solution containing 3% gluteraldehyde plus 2%
paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3. After fixation, the samples were
washed in 0.1 M cacodylate buffer, postfixed in 4% Millipore-filtered potassium
permanganate for 1 hour, washed in distilled water and stained en bloc with 1%
Millipore-filtered aqueous uranyl acetate for 1 hour. The samples were dehydrated in
increasing concentrations of ethanol, three changes in propylene oxide, infiltrated and
embedded in LX-112 medium. The samples were polymerized in a 70° C oven for 3
days. Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL),
stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a
JEM 1010 transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an
accelerating voltage of 80 kV. Digital images were obtained using the AMT Imaging
System (Advantage Microscopy Techniques Corp., Danvers, MA).

E. faecalis electron microscopy. DAP-sensitive and DAP-resistant ultrastructural
characteristics were assessed by transmission electron microscopy (TEM). Bacteria
were collected, washed and fixed with a 3% gluteraldehyde and 2% paraformaldehyde in
0.1 M cacodylate buffer, pH 7.3. Samples were incubated for 5 min in Millonig’s
solution followed by a 45 min incubation in 50/50 OsO4 /Millonigs solution. After 5 min
in ddH2O, samples were step-wise dehydrated using increasing concentrations of ethanol
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solutions as follows: 5 min in 50% ethanol, 10 min in 70% ethanol, 10 min in 95%
ethanol, washed 3 times for 10 min in 100% ethanol. Dehydrated samples were washed
3 times for 10 min in propylene oxide, followed by incubation in 50% LX-112 for 120
min, then 100% LX-112 for 120 min and were imbedded in BEEM capsules and
incubated in a 70o C oven overnight to polymerize. To section the tissue, 500 nm
sections were cut from each block using a glass knife on a Leica Ultracut R microtome
and were stained with 0.5% Toluidine Blue for 1 minute on a hot plate at 80 °C. Slides
were washed and inspected for fitness. The best blocks were then trimmed and thin
sections (80 nm & 100 nm) were cut using a DiATOME diamond knife, one each of the
two thicknesses were floated on either 100 or 150 mesh copper grids (Electron
Microscopy Sciences) and heat fixed in a 70 °C oven for at least one hour. The grids
were stained for 15 minutes using 2% uranyl acetate, rinsed with ddH2O, stained 5
minutes in Renold's lead citrate, rinsed and dried in 70 °C oven. The specimen grids
were imaged in a JEOL 1200 transmission electron microscope at 60kV with digital
images collected using a 1k X 1k Gatan BioScan camera, Model 792, on a JEOL JEM1400 cryo-transmission electron microscope. To quantify the number of cell division
events (cells with a septum), cells were counted in 5 random consecutive fields in two
blinded experiments. Similarly, the average cell wall thickness was determined by
measuring a minimum of 3 times per cell on cells in 5 different fields. CW thickness
was measured from the outer border of the CM to the outer edge of the CW. Mean (+
SD) CW thickness was determined for each strain and mean differences compared with a
t-test.
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Liposome Formation. E. coli extract, 1,2-distearoyl-sn-glycero-3-phospho-L-serine
(PC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (PE), 1,2-dioleoyl-sn-glycero-3phosphatidylglycerol (PG), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (PS),
cholesterol, N-(7-nitro-2,1,3-benzoxaidasol-4-yl)-PE (NBD-PE) and N-(rhodamine B
sulfonyl)-PE (Rh-PE) were procured from Avanti Polar Lipids (Alabaster, AL). All
phospholipids were used without additional purification. The fluorescent dyes were
dissolved together with unlabeled lipid. Solvent was evaporated under a steady stream
of argon. After the solvent evaporation, lipids were resuspended to a concentration of
1mg/mL in PBS and sonicated for 10 minutes. Subsequently, the preparation was stored
at 4°C until use. For the FRET measurements liposomes were made with 5% fluorescent
lipid (NBD-PE or Rh-PE) and 95% unlabeled lipid, by weight. For specific lipid
interactions, increasing weight percentages of PC, PS, PE, or PG were added to E. coli
extract. All assays were performed in triplicate with average and standard deviation
shown.

Flourescence resonance energy transfer (FRET). To determine the ability of
D(KLAKLAK)2

to disrupt liposomal membranes, increasing peptide concentrations

where added to an equal mixture of Rh-labeled and NBD-labeled liposomes. After 24 h,
fluorescence transfer was measured using a Spectramax M5 spectrophotometer. The
excitation wavelength was 460 nm (excitation wavelength of NBD-PE) and the emission
spectrum was measured between 500-620 nm (534 nm emission of NBD-PE and 590 nm
emission of Rh-PE) with bandwiths: excitation 9 nm and emission 15 nm.
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GUV formation. A thin film (~300 µL) of 1% agarose in deionized water was spread
onto a glass slide and then dried at 40°C for 3 hours. A mixture of E. coli extract and RhPE (30 µl) in chloroform was painted across the agarose film and allowed to dry under
vacuum pressure for 2h. Slides were then placed into 150 mM KCL buffer and the
agarose was allowed to re-hydrate for a minimum of 1h. Pictures were taken 5 seconds
after the addition of D(KLAKLAK)2. Diluent alone (KCl buffer) was used as negative
control. All assays were performed a minimum of 3 times with representative data
shown.

Gram-negative membrane potential measurements. Bacteria were collected from a
mid-exponential culture, washed in buffer (5mM HEPES pH 7.2, 5mM glucose), and
resuspended in the same buffer to OD600nm of 0.05. diSC3(5) and EDTA were added to
the bacterial suspension at final concentrations of 0.4 µM and 0.2 mM EDTA,
respectively. The mixture was incubated in the dark for 1h to allow maximal uptake of
the diSC3(5). The osmotic gradient was equilibrated to a final concentration of 100 mM
KCl. Subsequently, the mixture was subjected to increasing concentrations of
D(KLAKLAK)2

in buffer. diSC3(5) fluorescence was monitored using a Spectramax M5

spectrophotometer at excitation of 622 nm and emission of 670 nm. Relative
fluorescence intensities were normalized to the effect of PBS, which was assigned a
value of 0% and 100% isopropanol, which was assigned a value of 100%. All assays
were performed a minimum of 3 times with representative data shown.
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Gram-negative outer membrane permeability. A 5mL overnight culture of bacteria
was used to inoculate 50 mL of LB broth. Mid-log phase bacteria were collected,
washed once and resuspended in HEPES buffer (5mM (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid) HEPES pH 7.2, 5 mM sodium azide) to a final
concentration OD600nm of 0.5. The bacterial suspension was added to a clean plastic
cuvette and the OD600nm was measured for 10 s. Lysozyme was then added to a final
concentration of 50 µg/mL and the OD600nm was measured for an additional 10 s.
Subsequently, increasing concentrations of D(KLAKLAK)2 in small increments (5-10 µL
at a time) were added to the sample. The turbidity of the sample was measured after the
lysis process stabilized (as seen by a stabilization in the OD600nm) and every 10 seconds
after stabilization for 30 seconds. Relative values were normalized to the effect of PBS,
which was assigned a value of 0% and 100% isopropanol, which was assigned a value of
100%. All assays were performed a minimum of 3 times with representative data
shown.

Erythrocyte hemolysis. Whole human blood was collected in EDTA and erythrocytes
were separated by centrifugation. The cells were washed with 150 mM NaCl, and
resuspended in PBS at a concentration of 108 erythrocytes/mL. The erythrocyte
suspension was incubated at 37°C with increasing concentrations of D(KLAKLAK)2.
After centrifugation, the hemoglobin released in the supernate was measured at 415 nm
after 48h. All assays were performed in triplicate with mean and standard error of the
mean shown.
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Surface charge in E. faecalis pair. Cell surface charge was measured using a modified
cytochrome c assay as described previously (304). Briefly cells were grown overnight in
brain-heart infusion broth (BHI), washed twice with 20 mM 3-(N-morpholino)
propanesulfonic acid (MOPS) buffer pH 7, and resuspended in the same buffer. Cells
were then incubated with 0.5 mg/ml cytochrome c for 10 minutes, pelleted and the
amount of cytochrome c remaining in the supernatant was determined
spectrophotometrically at 530 nm (the lower the amount of bound cytochrome c, the more
positively charged the cell envelope). All assays were performed in triplicate with
average and standard deviation shown.

CM permeabilization in E. faecalis pair. The highly sensitive LIVE/DEAD BacLight
kit was used in order to measure DAP-mediated CM permeabilization. Cells were grown to
mid-exponential phase in BHI, harvested and washed once in HEPES buffer (5mM
HEPES, 5mM glucose pH 7.2), then resuspended in the same buffer containing 5µM
SYTO-9, 30 µM propidium iodide and 50 mg/L calcium. Cells were allowed to
equilibrate for 10 min at room temperature and were added to 96-well plate with
increasing concentrations of DAP. Fluorescence was measured immediately with an
excitation wavelength of 488 nm and emission wavelength of 510 nm on a fluorescence
spectrophotometer. A negative control of buffer and a positive control of 100%
isopropanol were included. Percent fluorescence change was calculated setting
isopropanol control as 100% fluorescence change and buffer as 0% fluorescence change.
All assays were performed in triplicate with average and standard deviation shown.
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CM depolarization in E. faecalis pair. We also monitored the effect of DAP on CM
potential (ΔΨ) using diSC3(5) using the protocols described above with the following
modification: all assay buffers contained 50mg/L calcium. All assays were performed in
triplicate with average and standard deviation shown.
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Chapter III
D(KLAKLAK)2:

A Membrane Active Anti-Gram Negative Peptide

Introduction
(KLAKLAK)2 is a KLA-peptide that was originally assessed by the McLaughlin
group for its ability to kill both eukaryotic and prokaryotic cells (289). Jadvapoor et al.
designed several different amphipathic helical peptides with the sequences:
(KLAKKLA)n, (KLAKLAK)n (where n = 1,2,3), (KALKALK)3, (KLGKKLG)n, and
(KAAKKAA)n (where n = 2,3) to determine the effect of length, sequence, and structure
on biological activity. It was found that all of the leucine- and alanine-containing
peptides of the same length had similar MIC values. In addition, it was shown that the 7mers were inactive and the leucine-containing 21-mers were 2 times as potent at killing
bacteria as the 14-mers, while maintaining low mammalian-cell toxicity (289). Peptide
cytotoxicity against human erythrocytes and 3T3 mouse fibroblasts and antibacterial
activity against E. coli, P. aeruginosa, and S. aureus was tested. All of the leucine- and
alanine-containing peptides of the same length were found to have similar MIC values
and it was also found that the peptides were much less lytic toward human erythrocytes
than 3T3 cells. Since the first description, (KLAKLAK)2 has been widely used in cancer
research (305, 306, 307, 308, 309) as a pro-apoptotic moiety. Once internalized into
eukaryotic cells, AMPs such as (KLAKLAK)2 cause mitochondrial disruption by
triggering membrane permeabilization and swelling, resulting in release of cytochrome c
and induction of apoptosis (306).
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Here, we show that (KLAKLAK)2, is an effective antimicrobial against Gramnegative laboratory strains and clinical isolates. Despite the therapeutic promise, AMPs
development is hindered by their susceptibility to proteolysis. Here, we demonstrated
that an all-D enantiomer of (KLAKLAK)2, resistant to proteolysis, retains its activity
against Gram-negative pathogens. In addition, we have elucidated the specific site and
mechanism of action of D(KLAKLAK)2 through a repertoire of whole-cell and model
membrane assays.

Results
D(KLAKLAK)2

peptido-mimetic is proteolytically stable

We used mass spectrometry to determine the stability of D(KLAKLAK)2
compared to L(KLAKLAK)2 in the presence of human liver microsome extracts
containing Cytochrome P450 (CYP450), the major enzyme complex involved in drug
metabolism. To control for specificity, reactions were carried out in the presence or
absence of the NADPH co-factor. (KLAKLAK)2 peptide degradation in the absence of
NADPH would indicate metabolism from enzymes other then CYP450. Intact
D(KLAKLAK)2

was detected after 0, 30, 60 minutes and 24 hours confirming its

prolonged stability after continuous exposure to proteases (Fig. 3-1). All samples coincubated with NADPH contained a small amount of an unidentified adduct at +258
amu. A significant amount of an unidentified adduct at +105 amu was found after 24
hours specifically in the samples containing NADPH. (Fig. 3-2 and 3-3).
Contrastingly, the concentration of L(KLAKLAK)2 decreased over time and it
was completely degraded after 24 hours of exposure to liver microsome fractions,
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regardless of NADPH presence. Both N-terminal and C-terminal degraded products of
L(KLAKLAK)2

were found at 10 min, 30 min, and 60 min, and their identity was

verified by MS-MS profile. At 24 hours, some degraded products were still detected in
the samples with microsomes, but without NADPH. However, in the presence of
NADPH, degradation products were absent. The fact that there was no significant
difference between samples with and without NADPH, indicates that the degradation is
likely the result from metabolism from enzymes other than CYP450.

D(KLAKLAK)2

peptido-mimetic exhibits Gram-negative bactericidal activity

We determined the spectrum of D(KLAKLAK)2 activity against a variety of
bacteria and mold species using the broth dilution method published by the Clinical and
Laboratory Standards Institute (CLSI) in the USA (CLSI document M100-S16CLSI),
and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in
Europe (310). Table 3-1 summarizes the D(KLAKLAK)2 minimum inhibitory
concentration (MIC) measured for each strain tested. These data suggest that
D(KLAKLAK)2

is effective against Gram-negative bacteria such as P. aeruginosa, A.

baumannii, K. pneumoniae and E. coli. Molds such as Rhizopus oryzaye and Mucor sp.
and yeasts such as Candida sp. and the fungus Cryptococcus albidus were also found to
be sensitive to treatment with D(KLAKLAK)2. However, in this study, we investigated
only D(KLAKLAK)2 activity against Gram-negative bacteria.
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(KLAKLAK)2 + microsomes
(KLAKLAK)2 + microsomes + NADPH
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Figure 3-1. D(KLAKLAK)2 is resistant to degradation by human liver
microsomes. Intact D(KLAKLAK)2 was detected 0, 10, 30, 60 minutes and 24
hours after continuous exposure to microsomal enzymes in the presence
(blue line) and absence of NADPH (green line). L(KLAKLAK)2 concentrations
decreased rapidly over time with complete degradation observed within 24 hours
of exposure to liver microsome fractions both in the presence (black line) and
absence (red line) of NADPH.
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Figure 3-2. D(KLAKLAK)2 is resistant to degradation by human liver microsomes.
No degradation products of D(KLAKLAK)2 were found for up to 24 hours post
continuous exposure to microsomal enzymes. Representative mass spectra are shown at
(A) pre-incubation; (B) 60 minutes in buffer at 37oC; (C) 60 minutes post incubation with
pooled human liver microsomes and (D) 60 minutes post incubation with pooled human
liver microsomes in the presence of NADPH.
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Figure 3-3. L(KLAKLAK)2 is rapidly degraded during exposure to human liver
microsomes. Degradation products resulting from both N-terminal and C-terminal
proteolysis of L(KLAKLAK)2 were found at 10 min, 30 min, and 60 min.
Representative mass spectra are shown at (A) pre-incubation; (B) 60 minutes in
buffer at 37oC; (C) 60 minutes post incubation with pooled human liver microsomes
and (D) 60 minutes post incubation with pooled human liver microsomes in the
presence of NADPH.
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Table 1. MIC values for selected organisms tested for D(KLAKLAK)2 susceptibility.
Organism
Acinetobacter baumannii ATCC 19606
Pseudomonas aeruginosa (PAO1)
Pseudomonas aeruginosa (PA14)
Escherichia coli ATCC 25922
Klebsiella pneumoniae
Stenotrophomonas maltophelia
Cryptococcus albidus
Candida albicans
Staphylococcus aureus
Staphylococcus epidermidis
Mucor sp.
Rhizopus oryzaye
Aspergillus fumigatus
Fusarium oxysporum
Fusarium solani
Scedosporium prolificans
Aspergillus terreus
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MIC µg/ml
D(KLAKLAK)2
300
75
75
150
300
300
150
300
Not effective
Not effective
300
300
Not effective
Not effective
Not effective
Not effective
Not effective

Gram-negative bacterial growth is inhibited within 4 hours after exposure to
D(KLAKLAK)2

Although wildly used to determine antibiotic efficacy, MIC measurements do not
provide information about the dynamic interaction between the drug and bacteria. To
begin to understand the kinetics of this interaction, we compared time-kill curves of four
different strains at multiples of MIC for a period of 24 hours. D(KLAKLAK)2 treatment
induced significant bacterial growth inhibition ranging between two to four logs,
beginning at 4 hours after exposure. The effect of D(KLAKLAK)2 peptido-mimetic was
specific and dose- and time-dependent. However, substantially distinct killing rates were
observed among species (Fig. 3-4).
Considering the potential therapeutic use of this peptide, we next examined
whether D(KLAKLAK)2 exerts bactericidal activity against clinical isolates and if its
activity correlates with already acquired antibiotic resistance. We determined the MIC of
89 strains of P. aeruginosa, K. pneumoniae, and E. coli, respectively. Susceptibility
profiles indicated that the average MIC extends from 150 µg/ml for E. coli and P.
aeruginosa to 600 µg/ml for K. pneumoniae, respectively (Fig. 3-5). Comparative
analysis of routinely tested antibiotics susceptibility profiles (Table 3-2) and
D(KLAKLAK)2 effect

revealed no correlation between MDR and peptide susceptibility.

For instance, five E. coli clinical isolates are sensitive to all antibiotics tested, yet they
display average sensitivity to D(KLAKLAK)2 (150 µg/ml). Similarly, one E. coli clinical
isolate found to be resistant to most antibiotics tested, also exhibits average sensitivity to
D(KLAKLAK)2 (150

µg/ml). Among the twenty-five P. aeruginosa strains tested, four

were resistant to 5 to 8 antibiotics. However, these strains exhibited different
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Figure 3-4. D(KLAKLAK)2 inhibits growth of bacterial isolates within 4 hours of exposure.
Survival curves of PAO1, PA14, A. baumannii 19606 and E. coli 25922 after D(KLAKLAK)2
treatment at MIC (red line) 2X MIC (blue line) and 4X MIC (black line). D(KLAKLAK)2
induced bacterial growth inhibition within 4 hours of treatment when compared to the untreated
sample (green line).
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Figure 3-5. D(KLAKLAK)2 exerts bactericidal activity against clinical
isolates. MIC of clinical strains of E. coli (A), K. pneumoniae (B), and
P. aeruginosa (C) represented in µg/ml.
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Table 2. Clinical isolates resistance profiles. Red highlight indicates isolates
specifically mentioned in the text.

D(KLAKLAK)2
MIC µg/ml
37

150
300

Number of E. coli Isolates Resistant to Routinely Tested Antibiotics
0
1-4
5-8
9-12
13-16
0

3

0

0

0

D(KLAKLAK)2

5
9
2
1
0
3
4
1
0
0
Number of P. aeruginosa Isolates Resistant to Routinely Tested
Antibiotics
0
1-4
5-8
9-11
13-14

D(KLAKLAK)2

2
0
0
1
0
2
4
3
0
0
1
0
1
0
0
Number of K. pneumoniae Isolates Resistant to Routinely Tested
Antibiotics
0
1-4
5-8
9-12
13-14

MIC µg/ml
37
150
1200

MIC µg/ml
75
600
1200

0
0
0

0
10
5
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0
0
0

0
0
0

1
0
0

susceptibilities to D(KLAKLAK)2, spanning from the lowest to the second highest
concentration tested. The most striking example is represented by a K. pneumoniae
clinical isolate found to be resistant to all antibiotics tested, yet highly sensitive to
D(KLAKLAK)2 (75

µg/ml)..

Combination therapy has been shown to enhance antibiotic effectiveness and to
contribute less frequently than monotherapy to selection of resistance. We hypothesized
that D(KLAKLAK)2 may have synergistic activity with different classes of antibiotics.
As an example, we performed an in vitro time-kill assays to determine the activity of
D(KLAKLAK)2

in combination with piperacillin. Our results indicated a significant

synergistic effect within 4 hours after treatment at one half time the MIC for both
peptide and the conventional antibiotic piperacillin (Fig. 3-6).

D(KLAKLAK)2

activity is growth type and stage independent

Antibiotic susceptibility is routinely tested on planktonic microorganisms during
exponential growth phase. However, certain types of infections are caused by bacteria
growing as a biofilm. Adherent growth renders microorganisms 100 to 1000 times less
affected by antibiotics. To determine whether D(KLAKLAK)2 is active against bacterial
biofilms, we exposed a 24 hour old P. aeruginosa biofilm to increasing concentrations of
peptide. Similar to regular use antibiotics, D(KLAKLAK)2 was less effective against P.
aeruginosa biofilm (400 µg/ml) compared to free-growing cells (150 µg/ml). Notably,
the increase in susceptibility is less than 3 times suggesting that the peptide diffuses
efficiently through the biofilm and it is active against the metabolically active cells
present at the outer surface of the biofilm as well as the slow growing bacteria present in
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Figure 3-6. Synergistic effect of D(KLAKLAK)2 and piperacillin. Time-killing
curve showed that a combination of 1/2 MIC of D(KLAKLAK)2 with 1/2 MIC piperacillin
(red line) significantly enhanced the bactericidal effect when compared
to the activity of each drug alone: piperacillin, black line and D(KLAKLAK)2 blue line.
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the inner layers. Moreover, the activity of D(KLAKLAK)2 was found to be similar in
cation-adjusted Muller-Hinton and 10% fetal bovine serum RPMI suggesting that the
effects of D(KLAKLAK)2 are not media dependant (Fig. 3-7).
We subsequently reasoned that D(KLAKLAK)2 might also be active against
stationary growth phase bacteria. The ability of peptide to kill bacteria was measured
using the LIVE/DEAD BacLight kit. This assay employs a combination of two nucleic
acid stains used to distinguish live bacteria with an intact membrane from dead bacteria.
Live cells stained green with SYTO9 while dead bacteria stained red and yellow due to
SYTO9 and propidium iodide.
Unlike most conventional antibiotics that are active only against metabolically
active cells, the peptide equally affected exponential and stationary growth phase P.
aeruginosa (Fig. 3-8).

D(KLAKLAK)2

causes morphological membrane damage

In considering the amphipathic peptide mode of action, we first hypothesized that
the peptide might induce gross bacterial membrane damage. Electron micrographs of P.
aeruginosa incubated with freshly prepared D(KLAKLAK)2 at increasing concentrations
revealed clear morphologic evidence of membrane damage (Fig. 3-9).
To elucidate the underlying mechanism of action, we employed the lysozyme
lysis assay to determine outer membrane loss of integrity. When the bacterial membrane
is damaged, lysozyme gains faster access to its peptidoglycan substrate inducing rapid
cell lysis. A. baumannii 19606 and P. aeruginosa were exposed to increasing
concentrations of D(KLAKLAK)2 in the presence of lysozyme. The synthetic peptide
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Figure 3-7. D(KLAKLAK)2 inhibits biofilm growth. Twentyfour hour-old biofilm grown in LB (A) or 10% FBS RPMI (B)
was treated wtih increasing concentrations of D(KLAKLAK)2.
Both visual (A,B) and quantative (C) assesment demonstrated
dose-dependant eradication of biofilm.
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facilitated rapid lysozyme-induced cell lysis in a concentration dependant manner. P.
aeruginosa was completely lysed when exposed to16 µg/ml of peptide while only 60%
of the A. baumannii cells were destroyed at the same concentration. In contrast, a control
peptide had no effect on the bacterial membrane (Fig. 3-10). Since the MICs for A.
baumannii 19606 and P. aeruginosa are similar, genus-specificity suggests the
possibility that the peptide activity is time dependent.
Severe membrane injury usually results in membrane potential dissipation and
cell death due to loss of membrane function. We next sought to assess whether the loss
of membrane integrity results in membrane depolarization using the membrane
potential-sensitive dye diSC3(5). Bacterial exposure to D(KLAKLAK)2 induced a dose
dependant loss of membrane potential in all strains tested. However, a control peptide
had no effect on the bacterial membrane suggesting that D(KLAKLAK)2 activity is
specific (Fig. 3-11).

D(KLAKLAK)2

exerts its effect on membrane lipids

We next sought physical evidence of interaction between the peptide and cell
membrane lipids. Giant unilamellar vesicles derived from E. coli extract devoid of
membrane proteins were treated with 3 µg of D(KLAKLAK)2. Upon exposure to the
peptide, the liposomal membrane appeared punctuated suggesting lipid dissolution
perhaps as a result of D(KLAKLAK)2 insertion into the lipid bilayer (Fig. 3-12). This
effect was not seen with a control peptide (data not shown).
To further demonstrate lipid membrane dissolution, we investigated the ability of
D(KLAKLAK)2

to disrupt dual labeled liposomes using fluorescence resonance energy
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Figure 3-10. D(KLAKLAK)2 causes dose dependant membrane
permeability. D(KLAKLAK)2 induces membrane permeability in
PAO1, PA14, and A. baumannii 19606 (A, B, C black lines,
respectively). A control peptide (blue line) did not affect the membrane.
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Figure 3-11. D(KLAKLAK)2 treatment induces dose dependant loss
of membrane potential. D(KLAKLAK)2 causes loss of membrane
potential in PAO1, PA14, and A. baumannii 19606 (A, B, C black lines,
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Time after addition of D(KLAKLAK)2
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D

(KLAKLAK)2
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Figure 3-12. D(KLAKLAK)2 exerts its effect on lipid bilayers devoid of membrane
proteins. Giant unilamellar vesicles derived from E. coli extract devoid of membrane proteins
treated with 3 !g of D(KLAKLAK)2 (bottom row) showed clear punctate staining, evidence of
lipid membrane dissolution when compared to vehicle alone (top row).
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transfer (FRET). E. coli extract-derived liposomes labeled with either Nitro-2-1,3BenzoxaDiazol-4-yl (NBD) phosphatidylethanolamine (PE) (excitation at 460 nm and
emission at 534 nm), or rhodamine PE (excitation at 550 nm and emission at 590 nm),
were incubated with increasing concentrations of D(KLAKLAK)2. When the liposomes
are intact, the two fluorescent lipids are not in close enough proximity to yield an
efficient energy transfer. However, when D(KLAKLAK)2 disrupts the liposomal
membrane, free lipids are able to come in close contact leading to FRET. Energy
transfer causes a decrease in emission intensity at 534 nm (NBD emission) and a
corresponding increase in the emission intensity at 590 nm (rhodamine emission). In
support of our hypothesis, D(KLAKLAK)2 disrupted the integrity of liposomes indicated
by the emergence of an emission peak at 590 nm with the corresponding reduction of
the peak at 534 nm. A control peptide had no influence on liposome integrity whereas
ethanol disrupted both type of liposomes resulting in an energy transfer similar with the
one induced by D(KLAKLAK)2 (Fig. 3-13).

D(KLAKLAK)2

specifically disrupts bacterial membrane

Because the bacterial outer layer and eukaryotic membrane lipid composition are
different, we next asked whether D(KLAKLAK)2 interacts only with lipids specific for
the microbial outer layer. Phosphatidylethanolamine (PE), phosphatidylglycerol (PG)
and phosphatidylserine (PS) represent the most common bacterial lipids; whereas the
eukaryotic cell membrane has a more sophisticated composition with
phosphatidylcholine (PC) (24%) and cholesterol (17%) as major components. E. coli
extract-derived labeled liposomes supplemented with increasing concentrations of each
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Figure 3-13. D(KLAKLAK)2 disrupted the integrity of liposomes.
(KLAKLAK)2 disrupted the integrity of labeled E. coli extract derived liposomes
D
as indicated by the emergence of an emission peak at 590 nm with the
corresponding reduction of the peak at 534 nm. A control peptide had no
influence on liposome integrity whereas ethanol disrupted the liposomes
resulting in an energy transfer similar with the one induced by D(KLAKLAK)2 .
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specific lipids were incubated with D(KLAKLAK)2 and assessed for FRET. Consistently,
PE, PG and PS increased the susceptibility of liposomes to D(KLAKLAK)2 in a dose
dependent manner as demonstrated by a decrease in the peak at 534 nm complemented
by an increase in the peak at 590 nm (Fig. 3-14, A, B, C). As expected, the addition of
PC and cholesterol decreased the susceptibility of the E. coli extract liposomes to the
peptide (Fig 3-14 D, Fig. 3-15).
To further demonstrate that D(KLAKLAK)2 does not disrupt the eukaryotic
membrane, we tested erythrocyte hemolysis after treatment with increasing
concentrations of D(KLAKLAK)2. Hemolysis was assessed at 1, 3, and 48 hours of
exposure by measuring the absorbance hemoglobin release in the supernate at 415 nm.
In support of our hypothesis, the peptide had no hemolytic activity even after 48 hours of
treatment (Fig. 3-16).
Taken together, this data demonstrates that D(KLAKLAK)2 causes outer
membrane bilayer dissolution, which results in dissipation of membrane potential and
bacterial death. Moreover, the peptide acts specifically on the bacterial membrane
without disrupting the eukaryotic cell homeostasis.
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Figure 3-14. D(KLAKLAK)2 disrupted liposomes with composition similar to the bacterial membrane.
(KLAKLAK)2 disrupted the integrity of liposomes comprised of increasing percentages of PE, PG and
D
PS (A, B, C, respectively) lipids specific for the microbial membrane. PC containing liposomes (D) were less
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Figure 3-15. The effect of D(KLAKLAK)2 on the lipid bilayer was
significantly blunted with the addition of cholesterol to the liposomal
membrane. Cholesterol decreased the susceptibility of the E. coli extract
derived liposomes to the D(KLAKLAK)2 treatment in adose dependant manner
as shown with a increase in the peak at 534 nm and adrop in the peak at
590 nm.
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(KLAKLAK)2 treatment was insignificant when compared to the vehicle
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Chapter IV
Cell Envelope Analysis of Daptomycin-Susceptible Enterococcus faecalis and Its
Resistant Derivative that Arose During Therapy

Introduction
Enterococci are capable of causing a variety of potentially life-threatening
infections and, in the USA, are ranked as the second most common cause of nosocomial
infections after staphylococci (311). The current treatment of enterococcal infections has
become an enormous challenge for clinicians due to the fact that this organism
frequently exhibits multidrug resistance to the standard drugs of choice, namely
ampicillin, aminoglycosides (high-level resistance) and vancomycin. Moreover, there
has been a striking increase in the frequency of isolation and spread of VRE in hospitals
around the world which significantly increase mortality, hospital stay and/or
hospitalization costs (312). Enterococcus faecium is one of the “E’s” in the so-called
ESKAPE pathogens, highlighted by the Infectious Diseases Society of America as
problem pathogens requiring new therapies (313). Only two compounds are currently
FDA-approved for the treatment of VRE infections, linezolid and quinupristindalfopristin. Both have important limitations for the treatment of severe VRE infections
due to the frequent occurrence of clinical failures and recurrences, adverse toxicity
profile, limited spectrum, bacteriostatic effect against VRE and increased reports of
resistance. DAP is a lipopeptide antibiotic with in vitro bactericidal activity against
enterococci which was approved in 2003 for the treatment of skin and soft tissue
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infections (including for vancomycin-susceptible E. faecalis) and, in 2006, for the
treatment of bacteremia and right-sided infective endocarditis caused by Staphylococcus
aureus. Even though DAP does not have an indication for the treatment of VRE
infections, it has in vitro bactericidal activity against enterococci (including ampicillinresistant and VRE) and clinicians often use this compound off-label in severe
enterococcal infections due to the lack of reliable options (314). A major drawback to
the use of DAP for the treatment of VRE infections is the development of resistance
during therapy (301, 315, 316). Although little is known about the mechanism of DAP
resistance in enterococci, a critical step in DAP action is its interaction with the bacterial
CM in a calcium-dependent manner.
Previous studies in S. aureus indicate that the development of DAP resistance is
associated with important changes in the composition and function of the CM, cell
envelope and, in some cases, CW (317). It has been shown that there are multifactoral
pathways associated with DAP resistance in S. aureus and these pathways differ among
resistant strains (317, 251, 318).

In a recent study by Jones et al., using isogenic sets of

S. aureus clinical isolates from a DAP-treated patient, a variety of CM and cell envelope
alterations involving membrane fluidity, membrane phospholipid composition and
asymmetry, and surface charge were found to be associated with the DAP-resistant
phenotype (317). In addition to the phenotypic changes that have been described, there
are many examples of alterations in the CW function and structure that have been
proposed. In studies by Cui et al. (319) and Julian et al. (320) thickening in the CW was
described suggestive of a physical barrier to DAP reaching the CM. Also, it has been
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reported (321) that DAP-resistant S. aureus strains exhibit both (i) reduced membrane
depolarization, and (ii) reduced daptomycin binding to the cytoplasmic membranes.
In addition to the phenotypic changes observed in DAP resistant S. aureus
strains, genetic changes have also been identified. It has been found that mutations in
the genes mprF, yycG, rpoB and rpoC are induced by in vitro passages in sub-inhibitory
concentrations of DAP. These genetic mutations lead to changes in membrane charge
through lysinylation of PG (322) alteration of membrane fatty acid biosynthesis, and
changes in RNA polymerase, respectively.
Here we describe characterization of the CW and CM of a clinical pair of VRE
E. faecalis isolates obtained from the blood of a patient with fatal bacteremia before
(DAP-susceptible) and after (DAP-resistant) DAP therapy (DAP minimal inhibitory
concentrations of 1 and 16 µg/ml, respectively). Our findings indicate that, similar to S.
aureus, development of DAP-resistance in a vancomycin-resistant E. faecalis isolate is
associated with alterations of the CW and properties of the CM. However, the genes
linked to these changes in enterococci appear to be different from those described in S.
aureus.

Results
Development of DAP resistance is associated with marked ultrastructural changes
TEM revealed important differences in the cell morphology of the two isolates.
DAP-resistant cells tended to clump and formed aggregates with longer chains than
DAP-susceptible cells. At higher magnifications, the presence of multiple septal
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structures before complete cell separation was evident in the DAP-resistant cells (Fig. 41). The number of cells with a septum was consistently higher in the DAP-resistant
isolate compared to the DAP-susceptible isolate (P<0.05) (Fig. 4-2). Additionally, the
CW thickness of the DAP-resistant isolate was greater than that of the DAP-susceptible
isolate (average 18.12 + 2.23 and 10.43 nm + 1.34, respectively, p<0.05) (Fig. 4-3).

Alterations of CM potential are associated with the development of DAP-resistance
After determining that ultrastructural changes were present in the resistant E.
faecalis isolate, we furthered our analysis of the cell membrane to determine if
differences existed in DAP induced cell membrane potential loss. DAP dissipated the
CM potential in a concentration-dependent manner after 5 min of exposure in DAPsusceptible cells. Conversely, this effect was significantly blunted in the DAP-resistant
isolate (Fig. 4-4), indicating that emergence of DAP-resistance was associated with
alterations in the ability to depolarize the target CM.

DAP-resistance is related to changes in DAP-induced permeability.
Using the LIVE/DEAD BacLight Kit, the DAP-susceptible isolate was shown to
undergo a concentration-dependent increase in permeabilization after 5 min of DAP
exposure. Conversely, the DAP-resistant isolate showed striking reductions of DAPinduced CM permeabilization (Fig. 4-5). This effect was seen at different time points
from 10 min to 60 min.
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Figure 4-1. Ultrastructural changes of DAP-resistant isolate compared to
DAP-susceptible parental strain. Electron micrographs revealed surface
structures present on DAP-resistant (B) individual cells or connecting between
cells not observed in the DAP-susceptible isolate (A).
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Figure 4-2. DAP-resistant isolate undergoes septal formation before complete seperation. DAP-resistant
isolates (B) appeared to be less able to separate after cellular division indicated by a higher percentage of cells
with a septum (C) when compared to the DAP-susceptible parental strain (A).

A
Number of cells with a septum

A

DAP susceptible

Cell wall thickness (nm)
0

5

10

15

20

25

B

DAP susceptible

DAP resistant

Figure 4-3. DAP-resistant isolate displays a thickened CW when compared to the DAP-susceptible parental
strain. TEM micrographs of the DAP-resistant strain (A, bottom panel) reveals a thicker CW then the DAPsusceptible isolate (A, top row), average 18.12 + 2.23 and 10.43 nm + 1.34, respectively, p<0.05.
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Figure 4-4. DAP-resistant isolate is less susceptible to DAP-induced membrane
permeabilization. The DAP-resistant (open bars) isolate was less susceptible to
DAP-induced membrane permeabilization when compared to the DAP-susceptible
(filled bars) strain. The difference in susceptibility was seen as early as 10
minutes (A) after treatment with DAP at concentrations up to 60 µg/ml (5X the
MIC of the DAP-resistant isolate). This trend continued at measurements made
20, 30, 60 and 90 minutes (B, C, D, E, respectively) after treatment.
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Figure 4-5. DAP-resistant isolate is less susceptible to DAP-induced membrane potential loss when compared
to its DAP-susceptible parental strain. Induction of membrane potential loss measured via the DiSC3(5) assay
due to treatment with DAP caused a rapid depolarization of the DAP-susceptible strain beginning 5 minutes after
treatment (A, open bars). This effect was significantly reduced in the DAP-resistant (filled bars) at all time points
tested (A, B, C, D, E).
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Surface charge differences between DAP-resistant and DAP-sensitive E. faecialis
isolates.
The overall surface charge in the DAP-resistant and DAP-sensitive isolates was
investigated using the cationic cytochrome c molecule. Increased cell surface charge in
DAP-resistance in S. aureus is well documented, and the surface charge appears to play
an important role in the interaction of the antibiotic with the CM. It has been postulated
that a more positively charged cell envelope can presumably “repel” cationic AMPs
including DAP away from the CM and contribute to the development of resistance
(317). DAP-resistant cells had significantly higher amount of unbound cytochrome c,
indicating a more positively charged surface vs. the DAP-susceptible cells (P<0.05) (Fig
4-6).
Collectively, our results suggest that development of DAP-resistance in vivo in E.
faecalis is associated with profound ultrastructural changes in the CM, septal apparatus
and CW surface charge, DAP-induced membrane permeabilization and potential loss.
Taken together, all of these alterations likely enhance the organism’s ability to resist CM
damage caused by the positively charged calcium-associated DAP.
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Figure 4-6. DAP-resistant cell surface
more positivley charged. DAP-resistant
cells had significantly higher amount of
unbound cytochrome c, indicating a more
positively charged surface in comparison
to the DAP-susceptible cells (p<0.05).
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Although numerous organizations, independent clinicians and scientists
have alluded to the danger posed by the tremendous increase of infections caused
by MDR bacteria, the research and development of new antibiotics is lagging far
behind the ability of microorganisms to become resistant to current therapies
(323, 324). Recent reports focused on the identification of agents being
developed have shown that the number of antimicrobials in clinical trials is very
low and that most of these compounds are active against Gram-positive
pathogens (325, 313). These studies emphasize the danger posed by MDR
Gram-negative bacteria since none of the therapies in development display a new
mode of action (313, 325). The results reported here propose that severe outer
membrane injury may represent a platform for novel drug development against
Gram-negative bacteria.
Amphipathic AMPs have been previously shown to cause bacterial death
via membrane disruption, but the therapeutic promise is hindered by their
susceptibility to degradation, potential toxicity and high synthesis costs (326). A
synthetic peptide, L(KLAKLAK)2, revealed high bactericidal activity combined
with insignificant eukaryotic cell toxicity (289). Here we show that not only the
all D-enantiomer of the (KLAKLAK)2 peptide retains its antimicrobial activity
against Gram-negative bacteria but is also resistant to degradation by the
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CYP450 enzyme. We speculate that the ability to withstand proteolysis may
allow lower therapeutic doses, longer availability and improved cost efficiency.
Despite the constant use of MIC to determine antimicrobial susceptibility
and guide treatment, this method does not provide any insight into the
equilibrium of the bacteria-drug interaction. Moreover, the MIC provides
information exclusively about the susceptibility of free, actively growing
organisms. The sensitivity of quiescent, slow growing bacteria or biofilms to
antimicrobials remains unknown, and differs from the susceptibility of
exponential phase organisms. Therefore, a large number of infections receive
sub-inhibitory drug concentrations, potentially contributing to emergence of drug
resistance. The in vitro dynamic interaction of D(KLAKLAK)2 with several
bacterial species showed that the number of bacteria decreases by two to four
logs within 4 hours of treatment. Two commonly used P. aeruginosa strains,
PAO1 and PA14, revealed different growth inhibition profiles. At MIC, PAO1
growth abruptly decreased within 4 hours, however, by 10 hours the rate of
multiplication exceeded the peptide-induced killing rate. At concentrations
higher than the MIC, we observed dose- and time-dependent growth inhibition.
In contrast, PA14 was less sensitive to D(KLAKLAK)2. Although the growth
inhibition of PA14 was initially dose dependent, after 24 hours the overall
peptide activity was not significant. In the case of A. baumannii 19606 and E.
coli 25922, D(KLAKLAK)2 induced dose- and time-dependent growth inhibition
with cidal effect at all concentration after 10 hours and 24 hours, respectively.
The differences in susceptibility to D(KLAKLAK)2 may be attributed to several
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factors: i) species- specificity, ii) already acquired resistance to antimicrobials,
iii) growth conditions or iv) secretion of factors that may interfere with peptide
activity. Most likely growth conditions play an important role. As mentioned
before, MIC testing is performed under static conditions, whereas time-kill
curves involve culture aeration that may greatly affect the growth rate. Another
possibility is that drug sensitivity is altered by the type or stage of growth. In
fact, our data indicated that the peptide is able to dismantle 24-hour-old biofilm
grown on plastic plates. This raised the possibility that D(KLAKLAK)2 is active
not only against growing bacteria but also against quiescent cells or stationary
phase bacteria. Notably, live-dead microscopy assays indicated that the peptide is
active regardless of the growth stage. This observation is of crucial importance in
the context of persistent infections. Most commonly used antibiotics interfere
with protein, RNA, DNA, peptidoglycan and folic acid synthesis processes that
are active only in growing bacteria (327). In contrast, persistent infections are
caused by dormant or slow-growing organisms such those within biofilms. These
infections are hardly eliminated by commonly used antibiotics and therefore
more susceptible to acquiring resistance to antimicrobials.
To further distinguish the factors that influence D(KLAKLAK)2 activity,
we tested approximately 100 clinical isolates with different antibiotic
susceptibilities. Our data indicated a lack of correlation between already acquired
antimicrobial resistance and susceptibility to D(KLAKLAK)2. Furthermore,
combination therapy using piperacillin and D(KLAKLAK)2, both at one half MIC,
indicate a synergistic effect.
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The mechanism of amphipathic AMPs action has been fairly well
defined. Bacterial death occurs as a result of membrane permeabilization caused
by peptide insertion into the lipid bilayer (268). Electron microscopy studies
demonstrated membrane damage and formation of membrane blebs. Depending
on the agents used, cell death and membrane deterioration occur at the same time
or the membrane injury continues long after loss of cell viability. Similarly, we
observed ultrastructural membrane damage starting at treatment with 37.5 µg/ml
D(KLAKLAK)2

and more obvious at 150 µg/ml peptide after 25 minutes of

treatment. Using the lysozyme lysis assay, we showed that D(KLAKLAK)2
induced a loss of membrane integrity as measured by the ability of the peptide to
increase lysozyme access to its peptidoglycan substrate and induce cell lysis.
Surprisingly, amounts as low as 20 µg/ml D(KLAKLAK)2 created membrane
pores large enough to allow complete cell lysis suggesting that the actual lipid
bilayer damage is more intense than the modification observed in our electron
micrographs.
As noted previously, bacterial membranes serve not only structural
functions, but also support selective transport and energy storage (328).
Membrane destabilization promotes loss of membrane potential, ultimately
resulting in cell death. As shown by our results, D(KLAKLAK)2 treatment
induced dose-dependent membrane depolarization correlated with bacteria loss
of viability.
As shown by our model membrane assays, D(KLAKLAK)2 interacts
solely with lipids specifically found in the bacterial membrane and this
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interaction is inhibited by the addition of PC or cholesterol, components
predominantly present in the eukaryotic membrane. Targeted activity allows the
peptide to neutralize bacteria without perturbing the eukaryotic membrane.
Indeed, concentrations of bactericidal concentrations of D(KLAKLAK)2 had no
hemolytic activity. In agreement, we previously showed that untargeted peptide
could not induce apoptosis of KS1767 or MDA-MB-435 cells (309).
Taken together, our in vitro susceptibility and mechanistic studies suggest
that (KLAKLAK)2 maintains its activity against Gram-negative bacteria in the
all-D proteolytically stable form. Natural and synthetic AMPs have been
previously proposed as an alternative to antibiotics because their selective
activity against microbes and lack of ability to quickly induce resistance (329).
However, their high synthesis cost, instability, bioavailability and high sensitivity
to salt and serum, and occasional toxicity have been considered hindering
features for drug development (275). Although far from being ready for clinical
applications, we speculate that a stable peptide may allow higher bioavailability,
eliminate instability and improve cost-efficiency by using lower amounts of drug
for treatment. In addition, our data indicated that the peptide activity is not
influenced by either high salt or serum presence. Moreover, work performed in
our laboratory exploiting the pro-apoptotic D(KLAKLAK)2 capability revealed
fairly low toxicity at therapeutic concentrations. However, we acknowledge that
the toxicology profiles for cancer and infection may differ. Notably, the peptide
alone or in combination with commonly used antibiotics is also active against
persistent infections such as biofilms and MDR clinical isolates. In the event that
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the peptide displays high toxicity at the concentrations necessary to eliminate
infection in vivo, we propose that we could at least exploit this agent for
combination therapy, as coating component for biomedical devices or as topical
antibiotic.
In summary, we believe that the D(KLAKLAK)2 mode of action may
represent a stepping-stone for the development or improvement of drugs with
broad activity against the lipid bilayer. On this note, a D(KLAKLAK)2 variant
with improved pro-apoptotic activity has already been reported (330). Therefore,
our future experiments will focus on the engineering of divergent peptides with
improved antibacterial activity, defining the peptide activity to eliminate
infection in vivo, delineate its toxicological and pharmacokinetics profiles.
As previously stated, it is considered that development of resistance does
not represent an obstacle for AMPs clinical development. In 2003, the FDA
approved the lipopeptide antibiotic DAP. DAP is not, in its native form, a
traditional AMP. However DAP renders itself a de-novo AMP in the presence of
calcium ions. DAP is proposed to cause bacterial cell death in the same manner
as traditional AMPs. It is widely accepted that DAP first binds to the Grampositive bacterial membrane followed by rapid depolarization resulting in a loss
of membrane potential which leads to protein, DNA and RNA synthesis
inhibition, resulting in bacterial cell death.
Recently, Gram-positive strains with decreased susceptibility to DAP
have been reported, yet the mechanism of resistance in enterococci remains
unknown. Our findings indicated that, similar to S. aureus, development of DAP-
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resistance in a vancomycin-resistant E. faecalis isolate is associated with
alterations of the CW and CM properties. However, the genes linked to these
changes in enterococci appear to be different from those described in S. aureus.
The treatment of modern-day enterococcal infections has become a major
challenge since there is a lack of reliable options to treat ampicillin-resistant
VRE infections. The off-label use of DAP is often employed in the treatment of
severe enterococcal infections including VRE or those exhibiting high-level
resistance to aminoglycosides. However, a major drawback for the successful use
of this antibiotic is the emergence of resistance during DAP therapy. Moreover,
enterococci are less susceptible in vitro to DAP than S. aureus with a breakpoint
four-fold higher than for S. aureus (< 4 µg/ml vs < 1 µg/ml, respectively) (CLSI
document m100-s20). Thus, an understanding of the molecular events that lead to
the development of DAP-resistance is of vital importance when designing new
therapeutic strategies for salvaging the use of DAP against VRE (e.g., higher
dose schemes or combination therapies) and has the potential to identify or
validate new targets for the development of novel antimicrobial agents against
these organisms.
An essential event for the activity of DAP is the calcium-mediated
interaction of this antibiotic with the CM. The interaction of DAP with the CM of
enterococci is not as well defined as the interaction of antimicrobial peptides
with Gram-negative bacteria. Gram-positive cells have a thick layer of
peptidoglycan that the antimicrobial peptide molecule must transverse to reach
the target site of action. Therefore, modifications to this barrier that make the
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peptide less able to interact with the membrane would reduce the effectiveness of
the peptide. We identified marked distortions of the CW, surface and septal
apparatus in the DAP-resistant isolate in our clinical strain pair set. Some of the
cell surface changes (e.g., cell surface protrusions) have not been previously
described with DAP resistance. These changes suggest that emergence of
resistance to DAP in enterococci during therapy is also related to important
alterations of CW homeostasis. Indeed, previous studies in S. aureus indicate that
inhibition of peptidoglycan biosynthesis and activation of the CW stress response
is involved in DAP action and non-susceptibility (331).
In addition, the surface charge appears to play an important role in the
interaction of the antibiotic with the CM and it has been postulated that a more
positively charged cell envelope can presumably “repel’ cationic AMPs,
including DAP, away from the CM and contribute to the development of
resistance (317). A major contributor of the cell surface charge is the
phospholipid composition of the inner and outer CM leaflets, such as the
negatively charged cardiolipin (CL) and positively-charged amino derivatives of
PG. In some S. aureus isolates, reduced susceptibility to DAP has been attributed
to a decrease in the overall cell surface charge as a result of modifications in
phospholipid content, mainly through an increased synthesis and translocation
(“flipping”) of the positively charged lysyl-phosphatidylglycerol (L-PG) from the
inner to the outer leaflet of the CM (317). Moreover, it has been shown that LPG attenuates membrane perturbations caused by cationic antimicrobial peptides
(332). Our findings suggest that, similar to S. aureus, development of DAP-
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resistance in vancomycin-resistant E. faecalis is also associated with increased
cell surface charge. However, unlike S. aureus, enterococci possess other aminocontaining PL apart from L-PG including arginyl-, alanyl-, and diglucosyl-PG
(333) which could also alter the CM charge or stabilize the CM and, thus, may
contribute to the DAP-resistance phenotype.
Taken together, we have shown that the emergence of DAP resistance
during therapy of VRE is associated with important alterations in DAP-induced
CM potential and permeabilization with an increase in net cell surface charge. In
addition, alterations of CM similar to those observed in S. aureus appear to play
a role in DAP resistance in VRE. Our results suggest that the development of in
vivo DAP resistance in VRE is associated with marked structural changes in the
cell envelope with alterations in cell division and increased CW thickness.
Notably, the genetic strategy used by enterococci appears to be different from
that described in S. aureus (personal communication, Cesar A. Arias, MD, PhD,
University of Texas Medical School). Indeed, none of the genes previously
associated with the emergence of DAP-resistance in S. aureus (319, 251)
appeared mutated in the DAP-resistant isolate compared to its DAP-susceptible
parental strain. Recent findings (unpublished, personal communication, Cesar A.
Arias, MD, PhD, University of Texas Medical School) provide compelling
evidence that changes in genes encoding CM phospholipid synthesis enzymes,
namely CL synthase and glycerophosphoryl diesterphosphodiesterase in E.
faecalis are important for development of DAP-resistance in enterococci.
Findings (unpublished, personal communication, Cesar A. Arias, MD, PhD,
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University of Texas Medical School) derived from genomic analysis of E.
faecalis also identified unique mutations in the genes encoding a three
component-regulatory system (LiaFRS, for lipid-II interacting antibiotics), not
previously associated with DAP-resistance in S. aureus. This unique system is
known to orchestrate the cell envelope response to antibiotics and antimicrobial
peptides in some Gram-positive bacteria (the genes are present in most
Firmicutes). The LiaFSR system has been well characterized in B. subtilis (334)
Streptocococus mutans and pneumococci (335). In B. subtilis and S. mutans, the
LiaFSR system is usually activated by the presence of antibiotics that disrupt CM
(i.e., bacitracin, daptomycin, ramoplanin, nisin and vancomycin (334). In B.
subtilis, LiaF is a membrane-anchored, negative regulator of LiaS (which is the
sensor protein of the system and also functions as a histidine kinase that
phosphorylates the response regulator, LiaR). LiaF interferes with the histidine
kinase autophosphorylation by direct interactions, thereby suppressing activation
of the cognate response regulator (LiaR) (336). Additionally, it is important to
note that there may be several pathways for the development of DAP-resistance
in enterococci, as shown in S. aureus (251, 337).
Taken together, we have shown that a synthetic AMP able to disrupt
bacterial membrane non-specifically is active against Gram-negative organisms
such as P. aeruginosa, K. pneumoniae, E. coli and A. baumannii, regardless of
their antibiotic resistance profiles. We speculate that targeting the cell outer layer
may represent a new strategy for antimicrobial development since the CM is
essential for microbe integrity as well as energy storage. Although the scientific
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community does not see development of resistance to AMPs as a concern,
reduced sensitivity of S. aureus and E. faecalis to de-novo AMP, DAP, emerged
as a result of treatment. Resistance associated with DAP include, most
importantly, modifications to the thick peptidoglycan layer surrounding the CM
of Gram-positive organisms. Since this is a Gram-positive specific cell feature,
the mechanism of resistance related to changes in the peptidoglycan layer is also
specific to Gram-positive cells.
In summary, the detailed analysis of the mode of action of the AMP
D(KLAKLAK)2

with lipid bilayers may represent a stepping-stone for the

development or improvement of drugs with broad activity against in Gramnegative bacterial membrane. We also believe that type of DAP resistance
acquired by enterococci and staphylococci will not affect the treatment with
D(KLAKLAK)2

because resistance to DAP in these organisms is related to Gram-

positive specific cell features such as the cell-wall.
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